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1 A brief historical survey of cathepsin D (1929-2005) 
1 A brief historical survey of cathepsin D (1929-
2005) 
The term “cathepsin” was introduced in 1929 [Willstätter & Bamann 1929] and the 
root of the word originates from the Greek, where it means “to digest”. In the 
beginning the term cathepsin was used to describe extracts of animal tissues 
containing a proteolytic system which showed proteolytic activity against hemoglobin 
at pH 3.5. Until that point, no further differentiation between the involved proteases 
had been made and so the first publication about isolation of this acidic proteolytic 
system from bovine spleen was entitled “The purification of cathepsin” [Anson 1940]. 
During these years, the term “cathepsin” was generally used to describe acidic 
intracellular proteases. 
Great efforts have been made to characterise and specify proteases such as 
papain [Bergmann et al. 1935], papain peptidase I [Bergmann et al. 1936], pepsin 
[Fruton & Bergmann 1939], trypsin [Bergman et al. 1939] and chymotrypsin 
[Bergmann & Fruton 1937] in order to understand their physiological function. At the 
same time it has been shown that the enzymatic action of proteases is not only 
restricted to peptide bonds in proteins of high molecular weight but also to 
constructed peptides and peptide derivatives. First peptide substrates were 
designed, synthesised and used for the determination of enzyme specificity and 
characterisation [Bergmann et al. 1937]. 
The peptide substrates enabled the scientist for the first time to distinguish 
between similar protease activities in a fast and simple way. According to this, the 
proteolytic system so far known as cathepsin proved to consist of at least three types 
of cathepsins in bovine spleen [Fruton et al. 1941]. These enzymes of the cathepsin 
system were correspondingly named cathepsin A, B and C. Further investigations 
were made and in 1957 cathepsin B (CatB) was isolated from bovine spleen 
[Greenbaum & Fruton 1957]. At the end of 1959 a new member of the cathepsin 
family was detected in bovine spleen and was consequently named cathepsin D 
because it did not hydrolyse any of the typical substrates for cathepsin A, B and C 
[Press et al. 1960]. The new found cathepsin D differed not only in its specificity from 
the other cathepsins but also in its mechanism of action, since the protease inhibitors 
iodacetamide (inhibitor for cysteine proteases), ethylenediaminetetraacetic acid 
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(EDTA, inhibitor for metalloproteases) and diisopropylfluorophosphate (inhibitor for 
serine proteases) had no effect on its proteolytic activity. These finding showed, that 
CatD is an aspartate protease (also known as acid protease or aspartic protease) in 
contrast to CatA which is a serine protease and CatB and CatC [Tallan et al. 1952] 
which are cysteine proteases. CatD has a pH optimum of 3.0 and represents two-
thirds of the proteolytic activity of crude spleen extract. The B chain of oxidized 
insulin [Sanger et al. 1949] was digested with pepsin and CatD and the generated 
peptides were identified, showing that the specificity of CatD, though more restricted, 
is similar to that of pepsin. CatD cleaved the B chain of oxidized insulin 
predominantly between leucine and tyrosine, phenylalanine and phenylalanine as 
well as between phenylalanine and tyrosine. Weak cleavage was observed between 
glutamic acid and alanine and between tyrosine and leucine [Press et al. 1960]. 
These newly introduced in vitro digestion experiments described for the first time the 
specificity of CatD to cleave peptide bonds preferably between hydrophobic and 
aromatic amino acids. 
The subsequent enzymatic investigations and characterisations were all more or 
less based on peptide substrates. Therefore great amounts of synthetic peptides 
with high purities were required. At this time peptides were commonly synthesised in 
solution and expensive purification and recrystallisation procedures had to be made 
following each coupling step. The synthesis of a decapeptide, for example, took up 
to one month or even longer and this fact clearly limited investigations based on 
peptide substrates. In the early sixties a new, fast and effective method for peptide 
synthesis was introduced by Merrifield [Merrifield 1963]. Peptide synthesis was 
carried out on solid phase using a copolymer of styrene which was cross-linked with 
1% divinylbenzene. The carboxyl group of the first amino acid was then coupled 
covalently to the resin and successively the peptide chain was elongated. The 
reason for this approach was that the growing peptide chain could easily be filtered 
and washed free of reagents and by-products. The combination of solid-phase 
peptide synthesis and in vitro digestion experiments smoothed the way for the 
characterisation of proteases. 
In 1962 another cathepsin, differing from CatD in pH optimum and charge at pH 
8.2 was isolated from rabbit bone marrow. The protease was also active against the 
synthetic substrates for CatA, CatB and CatC [Lapresle & Webb 1962] and was 
named CatE. The “enzyme brothers” CatD and CatE represented and still represent 
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the main aspartate proteases in mammalian cells and distinguishing between the two 
especially their involvement in cellular processes will become a biochemical 
problem, which will engage scientists for a long period of time [Arnold et al. 1997, 
Ostermann et al. 2004, Chain et al. 2005, Chou et al. 2005]. As recently as 2005 a 
specific substrate was described for CatE [Yasuda et al. 2005]. 
First assumptions were made to clarify the physiological function of CatD since 
cathepsins were known to be greatly elevated in muscular dystrophy [Tappel et al. 
1962, Iodice et al. 1965] and therefore contribute to the increased protein catabolism 
[Iodice et al. 1966a]. CatD has also been implicated in the pathological breakdown of 
cartilage matrix in rheumathoid arthritis [Fell & Dingle 1963, Ali 1964], osteoarthritis 
[Weston et al. 1969], digestion of immunoprecipitates [Wasi et al. 1966] and with 
collagen loss in involution of the uterus post partum [Woessner 1965]. 
During the next years cathepsins were purified from various tissues such as CatA 
and CatD, which were isolated from skeletal chicken muscle [Iodice et al. 1966b], 
lysosomal acid proteases from rabbit liver [Barrett 1967] and CatD from human and 
chicken liver [Barrett 1970]. 12 distinct forms of CatD were found in bovine uterus 
[Sapolsky & Woessner 1972] and 6 CatD isozymes in porcine spleen [Huang et al. 
1979]. For the first time Huang et al. showed, that CatD occurs as a single chain 
form with an apparent molecular weight of 50 kDa and a two-chain CatD form 
consisting of a light chain (15 kDa) and a heavy chain (35 kDa). Furthermore they 
showed that the N-terminus of CatD is homologous to other acid proteases such as 
pepsin and, that the N-terminal sequence of the single chain is apparently the same 
as the light chain sequence suggesting that these forms emerge from each other 
during biosynthesis. Further, the data of Huang et al. proved that CatD is a 
glycoprotein with at least four carbohydrate units, one in the light chain and three in 
the heavy chain. These preliminary results were studied in detail during the 1980s. 
Several purification methods and assays have been reviewed by Takahashi & Tang, 
1981. 
The knowledge of the biochemical properties of precursors and of their conversion 
to mature protein were well advanced in several systems, including secretory 
proteins [Campbell & Blobel 1976], membrane proteins [Toneguzzo & Ghosh 1978], 
viral proteins [Hershko & Frey 1975] and a few organellar proteins [Maccecchini et 
al. 1979, Cote et al. 1979]. The first results of the biosynthesis of lysosomal enzymes 
as precursors were published for β-galactosidase in macrophages of thioglycollate-
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treated mice [Skudlarek & Swank 1979]. In the same year the group of Erickson and 
co-workers suggested a possible pathway for biosynthesis and proved the existence 
of two proforms of CatD, a 43 kDa and a 46 kDa form as well as the enzymatically 
active 30 kDa form of CatD [Erickson & Blobel 1979]. These initial findings were 
studied in more detail in the following years leading to the following pathway for the 
biosynthesis of CatD. 
CatD (EC 3.4.23.5) is synthesized as non-glycosylated preprocathepsin D (MW 
43000) at the rough endoplasmatic reticulum and represents the primary translation 
product which is then transported via the Golgi complex to the lysosomes [von 
Figura & Hasilik 1986, Kornfeld & Mellman 1989]. A sorting tag has been identified 
which distinguishes molecules destined for lysosomes. Phosphate attached to the 6 
position of mannose residues on carbohydrate groups of soluble lysosomal enzymes 
is sufficient to target these molecules for lysosomal transport [Hasilik & Neufeld 
1980]. The initial selection step for the pathway is carried out by a single 
phosphotransferase located in the cis-Golgi which distinguishes soluble lysosomal 
enzymes from the numerous other proteins passing through this compartment 
[Kornfeld & Mellman 1989]. 
The pre-sequence (20 residues), which resembles the sequences of secretory 
proteins, is then cleaved off to yield glycosylated procathespin D (MW 46000). The 
pre-sequence functions as a signal sequence for translocation across the 
endoplasmatic reticulum membrane. A part of procathepsin D is secreted and can be 
detected in the culture medium. The intracellular amount of procathepsin D is further 
converted to enzymatically active single chain CatD by removal of the pro sequence 
(44 residues) which shows sequence homology to the 44 residue activation peptide 
of pepsinogen. The pro-sequence serves as an activation peptide that keeps the 
enzyme inactive during intracellular transport to the lysosome [Erickson et al. 1981]. 
The cleavage of the pro sequence has been shown to be pH-dependent (pH 3.5) 
and pepstatin-inhibitable leading to an increase in enzyme activity [Hasilek et al. 
1982]. During this processing step not only active single-chain CatD is generated but 
also three peptides which show inhibitory activity towards active CatD similar to the 
activation of pepsinogen [Puizdar & Turk 1981]. Activation of procathepsin D may 
occur via a unimolecular, autoproteolytic mechanism [Conner 1989]. Single chain 
cathepsin D undergoes further cleavage into a 15 kDa N-terminal domain (light 
chain) and a 30 kDa C-terminal domain (heavy chain). This cleavage results in the 
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removal of seven amino acid residues between the light chain and the heavy chain 
[Shewale & Tang 1984, Faust et al. 1985]. Finally, several amino acids are removed 
from the C-terminus of the heavy chain [Erickson & Blobel 1983]. 
In general all lysosomal enzymes are synthesized as inactive precursors which 
are processed either autocatalytically or by other enzymes to remove an N-terminal 
propeptide. The propeptide is thought to block the active site of the enzyme, thus 
preventing proteolytic activity. In addition to this inhibitory function, the propeptides of 
some aspartate proteases have been proposed to function in the folding of the 
nascent protein [Yonezawa et al. 1988] as proved to be the case for CatD [Conner 
1992]. 
The current known structural properties of human preprocathepsin D concerning 
disulfide bonds, subdivisions, actice site residues and glycosylation sites [Zhang et 
al. 2003] are summarised in Figure 1 [reviewed by Fusek et al. 2005]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 (A) Amino acid sequence of preprocathepsin D. Residues 1 to 18 are the 
signal peptide, residues 19 to 64 are the activation peptide, residues 65 to 
161 represent the light chain and residues 169 to 412 represent the heavy 
chain. (B) Schematic representation of structural features of Preprocathepsin 
D 
5 
1 A brief historical survey of cathepsin D (1929-2005) 
Lysosomal proenzymes, such as procathepsin D, have been shown to be 
associated with intracellular membranes in a mannose-6-phosphate-independent 
manner and therefore are sorted to the lysosome by another targeting system 
[Rijnboutt et al. 1991a, Rijnboutt et al. 1991b] differing from the common mannose-6-
phosphate pathway. It is a fact that the propeptides of vacuolar enzymes also 
contain a signal that is necessary for targeting to the organelle [Rothman et al. 1989] 
but this sorting mechanism does not account for CatD [Conner 1989]. Recently 
published data show, that the cysteine protease CatL is involved in CatD processing 
in order to generate the light chain and heavy chain from single chain CatD [Wille et 
al. 2004]. 
Rapid affinity chromatography is the method of choice for the isolation of 
proteolytic enzymes, especially endoproteases. The commonly used ion-exchange 
methods or gel chromatography require large amounts of sample from which the 
recovery is rather small. Since 1970 the aspartate protease inhibitor pepstatin was 
discovered [Umezawa et al. 1970] and used as active site titrant [Workman & Burkitt 
1979] and in immobilized form on sepharose for the isolation of CatD [Takahashi & 
Tang 1981, Kazakova et al. 1976] and CatE from rat spleen [Yamamoto et al. 1978]. 
The well established purification protocols permitted the isolation of CatD in large 
amounts and in high purity [Huang et al. 1979]. Isolation from porcine spleen was 
done by the group of Jordan Tang [Huang et al. 1979] as well as sequence analysis 
for the light [Takahashi & Tang 1983a] and heavy chain [Shewale & Tang 1983]. 
Further they showed that porcine spleen cathepsin D contains two glycosylation 
sites, one on each chain [Takahashi et al. 1983b]. Cloning and sequence analysis of 
cDNA for human CatD was done for the first time by Faust et al. 1985. 
The aspartate protease inhibitor pepstatin was introduced by Morishima et al. 
1970 and the interaction of human CatD with pepstatin was further investigated 
indicating that binding is strongly pH dependent so that in biological experiments 
near neutral pH, large molar excesses of pepstatin over CatD is required for efficient 
inhibition [Knight & Barrett 1976]. Presently the commonly used concentration of 
pepstatin for biological investigations is 10 µM and even 100 µM for cell cultur 
applications. 
In the last decade of the 20th century the pepstatin inhibited crystal structure of 
CatD was determined [Baldwin et al. 1993] as well as mapping of the CatD subsite 
preferences [Majer et al. 1997]. 
6 
1 A brief historical survey of cathepsin D (1929-2005) 
Aspartate proteases represent a large family of enzymes that catalyze peptide 
bond hydrolysis through an acid-base mechanism mediated by two catalytic aspartic 
acid residues (97Asp and 295Asp) [Davies 1990, Tang & Wong 1987] from which only 
one carboxyl group is protonated due to the fact that the total charge of the active-
site aspartic acids is -1 [Xie et al. 1997]. According to these properties aspartate 
proteases show an acidic pH optimum normally about pH 3-4. More recent results 
have also shown that pH dependent conformational switching of CatD modulates 
substrate specificity [Lee et al. 1998]. 
A set of inhibitory peptides had already been synthesized and tested for their 
inhibitory properties [Lin & Williams 1979] and new inhibitors based on the general 
structure 4-(morpholinosulfonyl)-L-Phe-P2-(cyclohexyl)Ala-P1’-P2’ [Rao et al. 1993]. 
The specificity of CatD was further investigated concluding the following preferences: 
a hydrophobic residue in P2 whereas residues capable of hydrogen bonding are also 
accepted but strongly positively charged amino acids are rejected; a preference of Ile 
in P3 over the smaller Ala was also observed [Scarborough et al. 1993]. Concerning 
the P2’ position CatD prefers positively charged side-chains whereas Glu in P2’ 
yielded a poor substrate and Asp in this position created a substrate that was not 
cleaved. Substrates bearing large hydrophobic side-chains at P3’ were excellent 
substrates [Beyer & Dunn 1998]. 
In the human genome about 500-600 proteases have been identified [Lopez-Otin 
& Overall 2002] from which about 60 are lysosomal proteases [Mason 1995]. 
Lysosomal proteases include a group of about 12 papain-like cysteine proteases. 
These cysteine proteases are all named cathepsin. The sole lysosomal papain-like 
cysteine protease which is not named cathepsin is legumain or asparaginyl 
endopeptidase (AEP) [Chen et al. 1997, 1998] and was characterised within our 
group [Schwarz et al. 2002]. Among the cathepsins only CatE and CatG are not 
lysosomal [lysosomal cysteine proteases were reviewed by Turk et al. 2000, Turk et 
al. 2001, Turk & Guncar 2002]. In Table 1 all known cathepsins are listed. 
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Table 1 Nomenclature recommended by the IUBMB and properties of human 
cathepsins (www.branda.uni-koeln.de, www.merops.sanger.ac.uk) 
 
 
Recommended 
Name 
EC 
number 
Classification Reference 
Cathepsin B 3.4.22.1 Carboxypeptidase, liberating C-terminal dipeptides 
Bond et al. 
1980, Barrett et al. 
1981 
Cathepsin C 3.4.14.1 
Aminopeptidase, release of a N-
terminal dipeptide except when P1 
is Arg or Lys, or P1’ or P2’ is Pro 
Planta et al. 
1964, Metrione et 
al. 1966 
Cathepsin L 3.4.22.15
Endoprotease, with preference 
for a residue bearing a large 
hydrophobic side chain at the P2 
position and does not accept Val at 
P1', compared to CatB, CatL 
exhibits higher activity towards 
protein substrates, but has little 
activity on Z-Arg-Arg-NHMec and 
no peptidyl-dipeptidase activity 
Kirschke et al. 
1988; Barrett & 
Kirschke, 1981 
Cathepsin H 3.4.22.16 Aminopeptidase and endoprotease 
Bromme et al. 
1987 
Cathepsin K 3.4.22.38
Endoprotease, the major 
determinant of specificity is P2, 
which is preferably Leu, Met > Phe 
and not Arg 
Inaoka et al. 
1995, Bromme et 
al. 1996 
Cathepsin F 3.4.22.41
Endoprotease, cleaves 
synthetic substrates with Phe and 
Leu in P2 better than Val 
Wang et al. 
1998, Wex et al. 
1999 
Cathepsin O 3.4.22.42
Endoprotease, hydrolyses Z-
Phe-Arg-NHMec and Z-Arg-Arg-
NHMec 
Velasco et al. 
1994 
Cathepsin S 3.4.22.27
Endoprotease, similar to CatL 
but with much less activity on Z-
Phe-Arg-NHMec and more activity 
after the Z-Val-Val-Arg compound 
Bromme et al. 
1975, Kirschke et 
al. 1989 
Cathepsin V 3.4.22.43
endoprotease, hydrolyses 
proteins, Z-Phe-Arg NHMec > Z-
Leu-Arg-NHMec > Z-Val-Arg-
NHMec 
Adachi et al. 
1998, Bromme et 
al. 1999 
C
ys
te
in
e 
pr
ot
ea
se
s 
Cathepsin X 3.4.18.1 
Carboxypeptidase which lacks 
action on C-terminal proline, weak 
endopeptidase activity 
Nagler et al. 
1999 
Cathepsin A 3.4.16.5 
Carboxypeptidase 
(also known as 
carboxypeptidase C) 
Miller et al. 1992 
Se
rin
e 
pr
ot
ea
se
s 
Cathepsin G 3.4.21.20
Endoprotease which preferably 
cleaves after Leu, Tyr, Phe, Met, 
Trp, Gln and Asn 
Tanaka et al. 
1985 
Cathepsin D 3.4.23.5 Similar to pepsin A, between hydrophobic residues 
Faust et al. 
1985, Scarborough 
et al. 1993 
A
sp
ar
ta
te
 
pr
ot
ea
se
s 
Cathepsin E 3.4.23.34 Similar to CatD 
Azuma et al. 
1989, Lapresle et 
al. 1986 
8 
1 A brief historical survey of cathepsin D (1929-2005) 
Cathepsins which are not yet included in the IUBMB recommendations, e.g. CatP 
[Puzer et al. 2005] and CatW (P56202, EC number 3.4.22. - not yet assigned) 
[Dalton & Brindley 2004] are not considered. CatT (EC number 3.4.22.24) is a 
cysteine protease but was only detected in rattus norvegicus to date [Pitot et al. 
1987] and therefore is not listed in table 1. 
The intracellular distribution of CatD as well as the relative amount of CatD in 
several cell types such as B cells, monocytes, dendritic cells, HeLa cells etc. still 
needs to be determined and will be clarified in the following chapters. 
In the early 1930s, proteases were typically determined using the trichloroacetic 
acid (TFA) method which uses denatured hemoglobin as substrate [Anson & Mirsky 
1932]. After digestion the intact hemoglobin was precipitated with TFA and the 
digestion products in the supernatant were then estimated colorimetrically with a 
phenol reagent yielding a blue colour with tyrosine and tryptophane moieties [Folin & 
Looney 1922, Looney 1926]. The detection of tyrosine and tryptophane was 
improved using the Folin and Ciocalteu reagent [Folin & Ciocalteu 1927]. The 
method has then been applied to the four known types of proteases at that time 
which were pepsin [Anson & Mirsky 1932], trypsin [Anson & Mirsky 1933], papain 
[Anson 1936] and already cathepsin [Anson 1936]. About two years later these data 
were confirmed using a simplified and standardised protocol [Anson 1938] which 
became the standard method for determination of protease activity. Currently, CatD 
activity is still determined using the hemoglobin assay with slight modifications 
[Shibata et al. 2002, Williamson et al. 2002, Bidere et al. 2003, Skrzydlewska et al. 
2005]. 
Recently, an enzyme-family assay based on microarrays was developed and used 
for determination of enzyme activities [Funeriu et al. 2005]. The new research results 
indicate, that the problem of specific and precise determination of enzyme activity is 
still ongoing. The presence and enzymatic function of CatD in various human cells 
and secrets such as sweat still needs to be investigated (see chapter 3 and 4). 
Multicellular animals are obligated to eliminate cells that are in excess or 
potentially dangerous. Therefore a programmed cell death program is needed in 
order to control cell numbers, tissue sizes and to protect the organism itself from 
rogue cells that threaten homeostatis. The term finally adopted for programmed cell 
death was apoptosis [Kerr et al. 1972]. The apoptotic cell death differs from 
9 
1 A brief historical survey of cathepsin D (1929-2005) 
pathological, necrotic cell death since only single cells are affected and not groups of 
neighbouring cells. 
The mechanism of apoptosis is very complex and depends on various factors. In 
general, there are two major apoptotic pathways in mammalian cells known: the 
death-receptor pathway and the mitochondrial pathway [reviewed by Hengartner 
2000, Boya et al. 2001, Kaufmann & Gores 2000]. Both pathways depend more or 
less on the activation of caspases (Cysteine Aspartate Specific ProteASEs) [Alnemri 
et al. 1996]. Consequently apoptosis research has focused on caspases and their 
role in programmed cell death. The concept, that caspases are the sole executive 
proteases in apoptosis now seems to be outdated by a growing body of evidence 
that strongly points to a role of lysosomes, especially lysosomal proteases in 
apoptosis. This phenomenon is meanwhile widely recognized and the term 
“lysosomal pathway of apoptosis” is accepted [reviewed by Guicciardi 2004]. 
Lysosomal permeabilization [Erdal et al. 2005] induced by the synthetic 
lysosomotropic detergent O-methyl-serine dodecylamide hydrochloride causes 
apoptosis [Li et al. 2000]. Cells undergo either apoptotic or necrotic cell death 
dependent on the amount of lysosomal enzymes released into the cytosol: selective, 
partial permeabilization triggers apoptosis and complete lysosomal breakdown 
triggers necrosis [Bursch 2001, Turk et al. 2002]. Once in the cytosol, lysosomal 
proteases interfere with caspases in the signalling pathway which has been shown 
for CatB [Salvesen 2001] or by direct cleavage of key cellular substrates [Leist & 
Jaattela 2001]. It has been shown that lysosomal extracts cleaves proapoptotic Bcl-
2-like proteins such as Bid or Bax and causes cytochrom c release followed by 
caspase activation [Stoka et al. 2001]. Detailed studies regarding CatD showed that 
it is rapidly translocated from lysosomes to the cytosol and increase the level of p53 
protein. According to this finding the CatD activity is drastically increased during 
apoptosis induced by oxidative stress [Kagedal et al. 2001]. Pepstatin A prevented 
cytochrom C release [Roberg et al. 1999] producing evidence for the involvement of 
CatD in apoptosis. It has been reported that pharmacological inhibition of CatD block 
cell death induced by interferon-gamma [Deiss et al. 1996] or tumour-necrosis factor-
α [Demoz et al. 2002]. Further investigations were made on the role of CatD in 
apoptosis and revealed, that CatD acts upstream of the caspase cascade i.e. before 
cytochrome c release and caspase activation at least in fibroblasts [Johansson et al. 
2003]. However, in HeLa cells no influence on apoptosis concerning cleavage of Bid 
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by CatD has been observed but papain-like lysosomal cysteine proteases proved to 
be actively involved in apoptosis [Cirman et al. 2004]. Focusing on CatD, recently 
published results indicate that CatD triggers Bax activation and that early apoptotic 
events can be inhibited with pepstatin A causing a delayed cell death [Bidere et al. 
2003]. 
At this time impressive results support the hypothesis that lysosomes and 
lysosomal proteases respectively may play a key role in apoptosis, but the 
mechanisms by which this occurs and the possible, functional relationship and/or 
cross-talks with other known apoptotic pathways remains largely unknown [Salvesen 
2001]. However, it has been shown that catalytically inactive CatD did not affect 
apoptosis [Tardy et al. 2003]. 
For further investigations concerning the intracellular localization of active CatD 
new methods have to be developed for the visualization of enzyme activity within 
living cells (see chapter 5). 
In the 1970s studies showed that coupling of poly-lysine to proteins enhances 
their cellular uptake [Ryser et al. 1978] which was the beginning of the area of so 
called cell-penetrating peptides (CPPs). A decade later it was shown that the HIV-1 
Tat protein is internalized by tissue culture cells [Frankel & Pabo 1988] and further 
investigations revealed, that the basic domain containing amino acids 48 to 60 (Tat 
peptide) to be responsible for this [Vives et al. 1997]. In the 1990s other CPPs were 
described such as penetratin [Derrossi et al. 1994], transportan [Pooga et al. 1998] 
and poly-arginine (R7 and R9) [Suzuki et al. 2002] for which Futaki et al. 
demonstrated, that the optimal number of arginine residues for the most efficient 
translocation is approximately 9 [Futaki et al. 2003]. 
CPPs such as transportan [Pooga et al. 2001], Tat peptide [Silhol et al. 2002] and 
nona-arginine [Luedtke et al. 2003] were used as vehicles for the cellular delivery of 
substances such as oligonucleotide analogues [Turner et al. 2005], antigenic 
peptides [Shibagaki & Udey 2002], peptide nucleic acids [Pooga et al. 1998], full-
lenghts proteins [Schwarze et al. 1999, Nagahara et al. 1998, Fawell et al. 1994] and 
drugs in general [reviewed by Trehin et al. 2004, Gupta et al. 2005]. A comparative 
study about protein cargo delivery by several CPPs was recently published [Säälik et 
al. 2004, see Graslund et al. 2004 and Lindgren et al. 2000 for reviews about CPPs 
in general]. The uptake of CPPs in cells can be accompanied by toxic effects 
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resulting from membrane perturbation at higher peptide concentration [Saar et al. 
2005]. 
The mechanism of uptake is not completely understood and still discussed up to 
now. In the late 1990s a direct transport through the lipid bilayer has been proposed 
[Vives et al. 1997, Derossi et al. 1996] since internalization is not significantly 
inhibited by depletion of the cellular ATP or by inhibitors of endocytosis. Whereas 
more recentely it has been shown that endocytosis is involved in the cellular 
internalization of Tat peptide and nona-arginine [Richard et al. 2003]. Especially for 
the TAT peptide a clathrin-dependent endocytosis mechanism was shown [Richard 
et al. 2005]. 
New methods for the precise quantification of cellular uptake of CPPs and their 
proteolytic fate needs to be developed to learn more about the involved 
internalization mechanisms [reviewed by Liu et al. 2003]. This problem will be 
discussed in more detail in chapters 5 and 6 respectively whereas a new quantitative 
method for the detection of internalized fluorescent peptides will be described. 
The functional linkage between apoptosis and cancer has been recently shown 
and reviewed by Kaufmann & Gores 2000, indicating that some oncogenes act by 
inhibiting cell turnover rather than enhancing proliferation e.g. myc [Evan et al. 1992, 
Vaux et al. 1998]. 
In general cysteine cathepsins [for review see Jedeszko & Sloane 2004] and in 
particular CatD [for review see Nomura & Katunuma 2005] are known to be involved 
in the pathology of various forms of cancer such as breast cancer [Foekens et al. 
1999, Vetvicka et al. 2002], colorectal cancer [Skrzydlewska et al. 2005] or lung 
cancer [Vetvicka et al. 2004]. Recent studies could even show that defective 
acidification of intracellular organelles results in secretion of CatD in cancer cells 
[Kokkonen et al. 2005]. 
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2.1 Enzymes and chemicals 
CatD (bovine spleen and human liver) was purchased from Sigma (Taufkirchen, 
Germany) and stored as a 32.3 µM stock solution in 0.1 M citric acid, pH 4.5 at -20 
°C prior to use. Pepstatin A, Zwittergent 3-12 and Rink amide resin were purchased 
from Calbiochem-Novabiochem (Schwalbach, Germany). All other chemicals and 
solvents were from Merck (Darmstadt, Germany). Fmoc amino acids were 
purchased from MultiSynTech (Witten, Germany) for the synthesis of the CatD 
substrates I, II, III and for all DCD-1L derived peptides and LL-37. 
Standard chemicals for the synthesis of R9-CatD-substrate were obtained from 
Fluka (Deisenhofen, Germany) and Merck (Darmstadt, Germany). All solvents were 
p. a. grade. Fmoc-amino acids were purchased from Novabiochem (Heidelberg, 
Germany), Senn Chemicals (Dielsdorf, Switzerland), and Orpegen Pharma 
(Heidelberg, Germany). Fmoc-Lys(Dde)-OH was purchased from Novabiochem 
(Läufelfingen, Switzerland). Rink amide resin was from Rapp Polymere (Tübingen, 
Germany). The isomeric mixtures of 5(6)-carboxyfluorescein (Fluo) and 5(6)-
carboxytetramethylrhodamin (Tamra)-N-succinimidylester were from Fluka 
(Deisenhofen, Germany). 
Bafilomycin A1 was obtained from Tocris Biotrend, Bristol, UK and chloroquine 
diphosphate from Fluka [Bowman et al. 1988, Clague et al. 1994, de Duve et al. 
1974, Kozak et al. 1999]. The bacterial metabolite lactacystin was purchased from 
Prof. Corey, Harvard University, Boston, USA) and Pepstatin A from Bachem, 
Bubendorf, Switzerland. The covalent cysteine protease inhibitor E-64d was 
purchased from Bachem. 
 
2.2 Solid-phase peptide synthesis 
Peptides were synthesized using standard Fmoc/tBu chemistry [Fields et al. 1991] 
and synthesis was performed on the multiple peptide synthesizer Syro II 
(MultiSynTech, Witten, Germany) on a 0.025 mmol scale using a six fold molar 
excess of Fmoc amino acids (MultiSynTech, Witten, Germany) on TCP-resin 
(PepChem, Reutlingen, Germany). All other reagents and solvents for peptide 
synthesis were purchased from Merck KGaA (Darmstadt, Germany). In situ 
13 
2 Materials and methods 
activation was performed using TBTU (6 eq.) and HOBt (1 eq.) followed by the 
addition of N-methylmorpholine (12 eq.) in DMF. After completion of the automated 
synthesis, the resin bound peptides were Fmoc-deprotected using 60% (v/v) 
piperidine in DMF twice for 15 min and washed subsequently with DMF, isopropanol 
and diethyl ether. To release the peptides from the resin and to remove the side 
chain protecting groups the following solution was used: 95% (v/v) TFA containing 
3% (v/v) thioanisol, 3% (w/v) phenol and 2% (v/v) ethanedithiol. The peptides then 
were precipitated in diethyl ether, dried and dissolved in 80% (v/v) tert-Butanol in 
water followed by lyophilisation. Crude peptides were purified using preparative 
reversed-phase high-performance liquid chromatography (RP-HPLC) and identity of 
the peptides was confirmed using electrospray ionization mass spectrometry (ESI-
MS). Peptide purities were determined via analytical RP-HPLC and proved to be 
higher than 97 %. The peptides were stored at 4 °C until use. 
 
2.3 Synthesis of the CatD-substrates I, II and III 
2.3.1 Synthesis of Fmoc-Lys(biotin)-Rink amide resin 
Fmoc-Lys-OH (368.4 mg, 1.0 mmol) was dissolved in 8 ml DMF and reacted with 
biotin-OSu (341.4 mg, 1.0 mmol) and NMM (111 µl, 1.0 mmol) for 6 h. The reaction 
mixture was extracted with chloroform, washed twice with 4 M KHSO4, water and 
finally evaporated to dryness. The obtained Fmoc-Lys(biotin)-OH derivative was 
coupled to Rink amide resin using the TBTU/HOBt coupling method. After this step 
the remaining free amino groups were blocked by acetylation with acetic 
anhydride/DIPEA/DMF (1:1:8, v/v/v) twice for 30 min. The degree of coupling was 
estimated to be 0.35 mmol/g. 
 
2.3.2 Solid-phase peptide synthesis (SPPS) 
The peptide substrates were synthesised by solid-phase synthesis using the 
standard Fmoc/tBu protocol [Fields et al. 1991] on the multiple peptide synthesizer 
Syro II (MultiSynTech, Witten, Germany) on a 0.025 mmol scale using a six fold 
molar excess of Fmoc amino acids. Side chain protecting groups were: tBu for Glu, 
Asp and Ser, Boc for Lys, 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) 
for Arg and Cys was Acm-protected. 
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In situ activation was performed using TBTU (6 eq) and HOBt (1 eq) followed by 
the addition of NMM (12 eq). After the completion of the coupling the resin bound 
peptides were Fmoc-deprotected using piperidine/DMF (2:3, v/v twice for 15 min) 
and washed subsequently with DMF, isopropyl alcohol and diethyl ether. 
 
2.3.3 On-resin labelling of substrates with Amca 
The fluorophore Amca (7-Amino-4-methylcoumarin-3-acetic acid) was coupled at 
a three fold excess directly to the α-amino group of the side chain-protected resin-
bound peptide in DMF using the TBTU/HOBt activation method for 3 h in the dark. 
Subsequently the resin was washed with DMF, isopropyl alcohol, diethyl ether and 
then dried. 
 
2.4 Kinetic characteristics of substrate I, II and III 
To measure the initial rates of substrate proteolysis and to determine the kinetic 
parameters of the substrates, digestion was monitored using RP-HPLC. Hydrolysis 
of substrates was performed in 48 µl of 50 mM Gly/HCl buffer (pH 3.5) containing 1 
µl of a 0.32 µM CatD solution. CatD dilutions were prepared in 0.1 M citric acid pH 
5.0 containing 0.05% (v/v) Triton X-100. The reaction was started by adding 1 µl of 
the appropriate substrate solution so that the final substrate concentration was 
between 5 and 80 µM. The reaction was performed at 37 °C. 
Every 2 min 2 µl of the reaction mixture were removed and added to 38 µl stop 
solution (H2O/ACN/TFA/Zwittergent 3-12, (94:5:1:0.2, v/v/v/w)). The obtained 
solutions were applied to an analytical C8 column (Nucleosil 100, 125 × 2 mm, C8 
column, 5 µm particle diameter, Wicom, Heppenheim, Germany) and eluted with a 
0% to 80% gradient of solvent B for 40 min. The HPLC column eluent was analysed 
measuring fluorescence emission at 450 nm following excitation at 350 nm using a 
fluorescence HPLC monitor RF-535 (Shimadzu, Duisburg, Germany). The peak of 
fluorescently labelled digestion product and the peak of undigested substrate were 
integrated and the amount of converted substrate in µM was determined. 
Then the initial velocity was calculated from the linear part of the cleavage curve 
which proved to be between 1 and 10 min. The Km (µM) and Vmax (µM × s-1) values 
were determined using the Lineweaver-Burk method. The kcat values (s-1) were 
calculated from the equation: 
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where [CatD]total is the total enzyme concentration in µM and Vmax is the maximal 
velocity in µM × s-1.  
 
2.5 Digest & pull down assay 
The cleavage of the peptide amide substrates was performed in 48 µl 50 mM 
Gly/HCl buffer (pH 3.5) containing protease inhibitors (2 mM phenylmethanesulfonyl 
fluoride and 20 µM leupeptin for the inhibition of serine proteases, 10 mM EDTA for 
the inhibition of metalloproteases and 10 mM iodacetamide for the inhibition of 
cysteine proteases). 
For the digest & pull down assay 1 µl of a 0.5 mM substrate solution in 50% (v/v) 
DMSO was used. The appropriate sample volume of the cell fractions containing 0.5 
µg total protein determined according to Bradford [Bradford 1976] was then added. 
The calibration curve was determined using the appropriate sample volume of CatD. 
After 10 min at 37 °C, 90 µl stop solution were added to 10 µl of the reaction 
mixture. The fluorescence of a 50 µl aliquot of the solution was then measured using 
the microplate reader Spectra Fluor (Nunc, Wiesbaden, Germany) at an emission 
wavelength of 465 nm with excitation at 360 nm, obtaining F1 in fluorescence units 
(FU). This solution was then added to 5 µl of streptavidin-coated magnetic beads 
(MagPrep® Streptavidin Beads by Merck, 1 µm, 1.4 g/l, 1012 particles/g). Magnetic 
beads were rinsed twice for 2 min with 50 mM Gly/HCl buffer (pH 3.5) before 
application. We determined that 2 µl of the magnetic beads suspension captures up 
to 0.1 nmol biotinylated peptide. The mixture was stirred and kept at RT for at least 
10 min but not longer than 30 min. Longer incubation leads to an increase of 
unspecific binding. The solution should be homogeneous for complete binding of the 
biotinylated molecules to the streptavidin-coated magnetic beads. After 10 min the 
magnetic beads were separated using a permanent magnet (after 1 min the 
supernatant should be clear). The fluorescence of 50 µl of the obtained supernatant 
was measured according to F2. The concentration of generated digestion product 
(DP) in µmol/l per min is calculated using the equation 
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where [S0] is the initial substrate concentration (µM) and t is the digestion time in 
min. [DP0] is the value of biotinylated peptides not bound to the magnetic beads (µM) 
and has to be determined in parallel to each test series. 
 
2.6 Synthesis of R9-CatD-substrate 
The doubly-labeled peptide R9-CatD-substrate (Ac-RRRRRRRRR-Lys(Tamra)-
APISFFELG-εLys(αFluo)-CONH2) was synthesized using the previously developed 
Nα-carboxyfluorescein-labeled lysyl-Rink amide resin [Fischer et al. 2003]. The 
peptide RRRRRRRRR-Lys(Dde)-APISFFELG was assembled on this resin in a 15 
µmol scale as described above. For analytical purposes a small fraction of the 
peptide was cleaved off and analyzed (RRRRRRRRR-Lys(Dde)-APISFFELG-
εLys(Fluo)-CONH2, purity 80 % as determined by RP-HPLC, 214 nm, calc. [M+H]+ = 
3164.7 Da, exp. [M+H]+ = 3164.0 Da as determined by MALDI-MS). 
Derivatizations of the peptide were performed manually in 2 ml syringes on a 
shaker at RT. Reactions were stopped by washing the resins 3 times each with 
DMF, MeOH, DCM and diethylether. The synthesis of the doubly-labeled peptide 
was performed in a 5 µmol scale. The amino terminus of the resin-bound and side-
chain protected peptide was acetylated using 1 ml DMF/acetic anhydride/DIPEA 
(8:1:1, v/v/v). Deprotection of the Dde-protecting group was performed using 2 % 
(v/v) hydrazine monohydrate in DMF twice for 3 min. Then the free ε-amino group 
was reacted with 5(6)-carboxytetramethylrhodamine-N-succinimidyl ester (10 µmol, 
5.3 mg) in DMF (200 µl) containing DIPEA (25 µmol, 4.3 µl). After 16 h, the resin was 
thoroughly washed followed by cleavage off the resin and deprotection of the doubly-
labeled peptide amide. The peptide was dissolved in ACN/water (1:1, v/v), 
lyophilized and analyzed by RP-HPLC and MALDI-MS (see Figure 25). Afterwards 
the R9-CatD-substrate was purified by preparative RP-HPLC. 
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2.7 Cell culture 
HeLa cells were grown in a 5 % CO2 humidified atmosphere at 37 °C in RPMI 
1640 medium with stabilized glutamine and 2.0 g/l NaHCO3 (PAN Biotech, 
Aidenbach, Germany) supplemented with 10 % (v/v) fetal calf serum (PAN Biotech), 
100 U/ml penicillin, and 100 µg/ml streptomycin (Biochrom, Berlin, Germany). 
Confluent cells were passaged by trypsinization with 
trypsin/ethylenediaminetetraacetic acid (EDTA) (0.05/0.02 % (w/v)) (Biochrom) in 
PBS every third to fourth day. 
The EBV-transformed human B cell line Boleth (IMGT/HLA sequence database 
number: HC10329) and the human monocyte cell line U937 (ATTC number: CRL-
2367) were grown at 37 °C in tissue culture flasks (Nunc, Wiesbaden, Germany) with 
RPMI 1640 medium (containing 10% (v/v) fetal calf serum; 2 mM L-glutamine; 25 
mM Hepes; Invitrogen-Gibco, Karlsruhe, Germany) supplemented with 80 µg/ml 
gentamycin (Merck, Darmstadt, Germany) in a humidified atmosphere (5 % CO2/air). 
108 Cells were harvested (1000 rpm for 10 min, Heraeus-Christ Varifuge K) and 
subcellular fractionation was performed as previously described by Schröter et al. 
1999. The obtained fractions were crude cell extract (CCE), endosomal fraction (E) 
and lysosomal fraction (L). 
 
2.8 SDS-PAGE and western blot analysis 
2.8.1 Western blot analysis of subcellular fractions 
Subcellular fractions were separated by SDS-polyacrylamide gel electrophoresis 
(15 µg protein/lane) on a 15% separating gel and transferred to a PVDF-membrane 
(Amersham Biosciences, Freiburg, Germany) in a Novex mini-trans-blot-apparatus 
(Invitrogen, Karlsruhe, Germany). The membranes were blocked for 16 h at 4 °C in 
Tris buffered saline with Tween 20 (TBST, 0.15 M NaCl, 10 mM Trizma® Base, 
0.05% Tween 20 (v/v), pH 8.0) containing 10% (v/v) Roti® Block (Roth, Karlsruhe, 
Germany). Rabbit anti-human CatD (Calbiochem, Schwalbach, Germany) was 
diluted 1:5000 in TBST containing 10% (v/v) Roti® Block and incubated for 2 h. 
Subsequently, filters were washed 3 times in TBST and incubated for 1 h with 
horseradish peroxidase-conjugated goat anti-rabbit IgG (Jackson Immuno Research, 
West Grove, USA) diluted 1:10000 in TBST containing 10% (v/v) Roti® Block. After 
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washing the filters 3 times with TBST, western blots were developed according to the 
ECL protocol by Amersham Biosciences (Freiburg, Germany). 
 
2.8.2 Western blot analysis of HeLa cell lysate 
106 HeLa cells were lysed in 200 µl phosphate buffered saline (PBS) containing 1 
% (v/v) NP-40, 0.5 % (w/v) sodium desoxycholate and 0.1 % (w/v) sodium dodecyl 
sulfate (SDS) (all detergents were obtained from Sigma) complemented with 
protease inhibitors for tissue extracts (Sigma). The protein content of the lysate was 
determined using a commercially available Bradford protein assay kit (Bio-Rad 
Laboratories, München, Germany). Proteins were separated using SDS-
polyacrylamide gel electrophoresis on a 10 % separating gel and then transferred to 
a PVDF-membrane in transfer buffer (195 mM glycine, 12.5 mM Tris/HCl, 0.01 % 
(w/v) SDS and 10 % (v/v) methanol) in a HEP-1 Panther Semi Dry Electroblotting 
System (OWL, Portsmouth, USA). The PVDF-membrane was first blocked for 1 h at 
RT with blocking solution (2 % (w/v) low-fat milk powder in PBST (PBS + 0.05 % 
(v/v) Tween) and subsequently incubated with rabbit anti-human CatD antibody at 4 
°C for 16 h (Calbiochem-Novabiochem Corporation, San Diego, USA; diluted 1:5000 
in blocking solution). Then the membrane was incubated with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (DakoCytomation, Glostrup, Denmark; 
diluted 1:5000 in blocking solution) for 1 h at RT. After washing the membrane 3 
times for 10 min with PBST, western blots were developed according to the ECL 
protocol by Amersham Biosciences (Freiburg, Germany). 
 
2.8.3 Western blot analysis of sweat 
Sweat samples were run on a 15% Bis-Tris (Bis-(2-hydroxyethyl)-glycin) 
separating gel with Tris-glycine running buffer (25 mM Tris-HCl, 192 mM glycine, 
0.1% (w/v) SDS, pH 8.3) and stained with Simply Blue™ Safe Stain (Invitrogen, 
Karlsruhe, Germany). Gel bands were excised and stored at -18 °C until digestion 
with trypsin. Western blot analysis was performed using a 10% Bis-Tris gel 
(Invitrogen, Karlsruhe, Germany) with MES ((2-(N-morpholino)ethanesulfonic acid) 
running buffer according to the manufacturer’s instructions. Proteins then were 
transferred to a PVDF (polyvinylidene difluoride) membrane (Amersham 
Biosciences, Freiburg, Germany) in a Novex mini-trans blot-apparatus (Invitrogen, 
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Karlsruhe, Germany). The membrane was blocked for 16 h at 4 °C in Tris buffered 
saline with Tween 20 (TBST, 0.15 M NaCl, 10 mM Trizma® Base, 0.05% (v/v) Tween 
20, pH 8.0) containing 10% (v/v) Roti® Block (Roth, Karlsruhe, Germany). Rabbit 
anti-human CatD (Sigma, Taufkirchen, Germany) was diluted 1:10,000 in TBST 
containing 10% (v/v) Roti® Block. After 2 h incubation membranes were washed and 
incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (Jackson 
Immuno Research, West Grove, USA) (1:10,000) for 1 h. Western blots were then 
developed according to the ECL protocol of Amersham Biosciences. 
 
2.9 Collection and preparation of sweat 
Human sweat samples from several healthy donors were collected from the 
surface of the face, neck or chest during physical exercise or in a hot environment as 
previously described [Schittek et al. 2001]. For some experiments sweat samples 
were pooled (pooled sweat). SDS-PAGE analysis was performed with 100 µl sweat. 
Before gel electrophoresis sweat samples were dialyzed (48 h) using a 1 kDa 
membrane Tube-O-Dialyzer™ (Geno Technology, St. Louis, USA) to remove small 
interfering substances such as salts. The resulting 150 µl sample were concentrated 
to dryness using a centrifugal vacuum concentrator (Savant SpeedVac® SPD111, 
Thermo Quest, Egelsbach, Germany) and then resuspended in 20 µl water. Western 
blot analyses and in vitro digestion experiments were performed with pure sweat, 
centrifuged at 1500 g (Biofuge pico, Kendro, Osterode, Germany). The obtained 
supernatants were stored at -80 °C until use. 
 
2.10 In-gel tryptic digestion and analysis of tryptic fingerprint 
Excised gel bands were diced to approximately 1 mm3 and washed once for 15 
min with water before being resuspended in 40 µl 50% (v/v) acetonitrile (ACN)/water 
and incubating for further 15 min. Gel pieces were then subsequently shrunk with 40 
µl 100% ACN and 40 µl of 100 mM (NH4)2CO3. Afterwards gel pieces were 
incubated for 15 min with a 1:1 solution of ACN and 100 mM (NH4)2CO3 and then 
vacuum-centrifuged to complete dryness. 40 µl of a trypsin solution (10 ng/ml) in 
digestion buffer (5 mM CaCl2 and 50 mM (NH4)2CO3) were added and incubated for 
45 min. The trypsin solution was removed and gel pieces were incubated for 16 h at 
37 °C in 50 µl digestion buffer. Tryptic peptides were eluted from the gel pieces by 
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covering them with 0.1% (v/v) TFA in water and sonicated for 30 min. The extraction 
step was repeated successively with 30% (v/v) ACN/water and with 60% (v/v) 
ACN/water. The obtained supernatants were pooled and vacuum centrifuged to 50% 
of the original volume to remove TFA and ACN. After adding 10 µl formic acid, 
samples were measured by MALDI-Re-TOF (time of flight) MS on a Voyager DE-
STR (Applied Biosystems, Foster City, CA, USA). Peptide fingerprints were exported 
for database matching, and subsequently identified using the Mascot program 
[Perkins et al. 1999] available through www.matrixscience.com. In certain cases the 
results of tryptic fingerprint analysis were not definite, thus the samples were 
additionally analyzed by automated LC-ESI-MS/MS using an Esquire 3000 plus ion-
trap mass spectrometer (Bruker-Daltonics, Bremen, Germany). The obtained MS/MS 
data were also analyzed using Mascot sequence query for probability based peptide 
identification. 
 
2.11 In vitro digestion of LL-37 and DCD-1L with CatD 
In vitro digestions of synthetic LL-37 and DCD-1L with CatD (Sigma, Taufkirchen, 
Germany) were performed in 50 mM Glycine/HCl buffer pH 3.5 and in sweat buffer 
pH 5.5 (40 mM NaCl, 10 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 1 mM NaH2PO4) 
(14). DCD-1L (24.9 µM) and LL-37 (26.7 µM) were incubated with 0.6 µM CatD for 8 
h at 37 °C. The reaction was stopped by addition of 25 µl stop solution (95% (v/v) 
ACN, 1% (v/v) TFA in water). 
Peptide fragments were separated via analytical RP-HPLC using a 125 × 2 mm 
Nucleosil 100 C 8 column (Wicom, Heppenheim, Germany) with the following solvent 
system: (A) 0.055% (v/v) TFA (trifluoroacetic acid) in H2O and (B) 0.05% (v/v) TFA in 
ACN/H2O (4:1, (v/v)). The column was eluted with a 5% to 80% gradient of solvent B 
for 40 min. UV-detection was carried out at 214 nm (UV detector SPD-10AV, 
Shimadzu, Duisburg, Germany). Manually collected fractions were subsequently 
analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-
MS) and Edman degradation on an automated 494A Procise peptide sequencer 
(Applied Biosystems, Darmstadt, Germany). The in vitro inhibition experiments were 
analyzed in the same way using a RF-10AXL fluorescence detector (Shimadzu, 
Duisburg, Germany) by measuring the emission at 450 nm following excitation at 
350 nm. 
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2.12 Determination of aminopeptidase activity 
Aminopeptidase activity was measured using the substrate H-Leu-AMC (Bachem 
AG, Bubendorf, Switzerland) (15 µM) according to the manufacturer’s protocol and 
25 µl pooled sweat to a final volume of 200 µl in PBS. Fluorescence signal was 
continuously measured using the microplate reader Spectra Fluor (Nunc, 
Wiesbaden, Germany) at an emission wavelength of 465 nm with excitation at 360 
nm. 
 
2.13 SELDI Protein Chip® Technology 
Sweat samples were analyzed by surface-enhanced laser desorption/ionization 
(SELDI) mass spectrometry [Wright 2002] on reversed-phase (H4) chips (Ciphergen 
Biosystems, Fremont, USA) which were equilibrated three times for 5 min in 
ACN/water (1:1, (v/v)). 1 µl human sweat was diluted into 2 µl binding buffer (50 mM 
sodium phosphate pH 6.5) and the chromatographic arrays were incubated in a 
humid chamber for 30 min. Then chips were washed three times for 5 min with 
binding buffer followed by a final water wash to remove interfering substances such 
as salts. After drying a saturated solution of sinapinic acid in ACN/H2O (1:1, (v/v)) 
supplemented with 0.5% (v/v) TFA was added and peptide masses were read from 
the array surface using a ProteinChip Reader (Ciphergen Biosystems, Fremont, 
USA). The instrument was externally calibrated using two different synthetic peptides 
(DCD-1L and DCD-1) and bovine insulin. Internal calibration was performed by 
adding 100 fmol of porcine dynorphin A, adrenocorticotropic hormone (1-24) and 
bovine insulin. The data obtained were analyzed using the ProteinChip Software 
(Version 3.0). 
 
2.14 Antimicrobial assays 
Antimicrobial activities of synthetic peptides were tested by the Department of 
Dermatology, University of Tübingen, using the colony-forming units (CFU) assay as 
previously described [Valore et al. 1998]. Escherichia coli (ATCC 25922) or 
Staphylococcus aureus (ATCC 25923) single cell colonies were cultured overnight, 
subcultured and grown to mid-exponential growth phase prior to the antimicrobial 
assay. Cells were washed twice with 10 mM Na-phosphate buffer pH 7.0 containing 
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10 mM NaCl. Bacterial concentration was estimated photometrical at 600 nm. 
Absorbance of 1.0 corresponded to 8.56*108 cells of E. coli and to 1.97*108 cells of 
S. aureus per ml. After dilution to a concentration of 106 CFU/ml in 30 mM Na-
phosphate buffer pH 7.0 containing 30 mM NaCl, 10µl of the dilutions were 
incubated at 37°C for 2h with 20µl various peptide concentrations in water. After 
incubation cells were diluted 1:100 in 10 mM Na-phosphate buffer pH 7.0 containing 
10 mM NaCl. Then 90 µl of the diluted bacterial suspension were plated in triplicates 
on blood agar. The plates were incubated overnight at 37 °C and the number of 
colonies were counted. Antimicrobial activity is expressed as percentage of cell 
death (PCD): 
 
1001 ×⎥⎦
⎤⎢⎣
⎡
⎟⎟⎠
⎞
⎜⎜⎝
⎛−=
control
sample
CFU
CFU
PCD
 
 
where CFUcontrol is the number of colony-forming units without peptide incubation 
and CFUsample is the number of colony-forming units of the appropriate sample. 
 
2.15 RP-HPLC for the R9-CatD-substrate 
The peptide was analyzed by analytical RP-HPLC using a H2O (0.1 % TFA) 
(solvent A)/ACN (0.1 % TFA) (solvent B) gradient on a Waters 600 System 
(Eschborn, Germany) with detection at 214 nm. The sample was analyzed on an 
analytical column (Nucleosil 100, 250 x 2 mm, C18 column, 5 µm particle diameter; 
Grom, Herrenberg, Germany) using a linear gradient from 10 % B to 100 % B within 
30 min (flow rate: 0.3 ml/min). The R9-CatD-substrate was purified by preparative 
RP-HPLC (Nucleosil 300, 250 x 20 mm, C18 column, 10 µm particle diameter; Grom, 
Herrenberg, Germany) on a Gilson (Bad Camberg, Germany) preparative system, 
equipped with a 321 Pump and a 156 UV/Vis Detector, flow rate: 10 mL/min. 
The purified R9-CatD-substrate was dissolved in DMSO at a concentration of 10 
mM. This stock solution was further diluted 1:20 in H2O. The peptide concentration 
was determined by UV/VIS-spectroscopy of a further 1:100 dilution in methanol. 
Absorptions of these solutions were then measured at 540 nm (ε = 95.000 
L/(mol⋅cm). 
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2.16 MALDI-MS 
1 µl of 2,5-dihydroxyacetophenone (DHAP) matrix (20 mg of DHAP, 5 mg of 
ammonium citrate in 1 ml of isopropyl alcohol/H2O (4:1, v/v)) was mixed with 1 µl of 
each sample (dissolved in ACN/water (1:1, v/v) at a concentration of 1 mg/ml) on a 
gold target. Measurements were performed using a MALDI-TOF (time-of-flight) 
system (G2025A, Hewlett-Packard, Waldbronn, Germany). For signal generation 20-
50 laser shots were added up in the single shot mode. 
 
2.17 Digestion of the R9-CatD-substrate with proteinase K for 
ratiometric measurements 
Fluorescence emission spectra were recorded at RT using an LS50B 
spectrofluorometer (Perkin-Elmer, Norwalk, USA). The spectra were corrected for 
the sensitivity of the detection system. The excitation and emission bandwidths were 
set to 10 nm. Purified R9-CatD-substrate (100 nM) was digested at 37°C with 
proteinase K (20 µg/ml, Sigma, Taufkirchen, Germany) in NP-40 lysis buffer (0.5 % 
(v/v) NP-40, 150 mM NaCl, 5 mM EDTA, 50 mM TRIS, pH 7.0). After 3 h the reaction 
was stopped by adding PMSF (final concentration 500 µM). Definite amounts of 
digested and undigested R9-CatD-substrate diluted in 100 nM in NP-40 lysis buffer, 
including 500 µM PMSF were mixed and fluorescence emission spectra of the 
solutions were recorded (excitation 492 nm). All digests and measurements were 
performed as duplicates. 
 
2.18 Fluorescence emission measurements in cell lysates 
HeLa cells were seeded in 12-well plates (Becton-Dickinson, Heidelberg, 
Germany) in serum-containing medium and grown to 90% confluency (300,000 cells 
per well). The cell layer was first washed with serum-free medium and incubated with 
250 µl serum-free medium (containing the indicated inhibitors) for 30 min. Then the 
R9-CatD-substrate was added at the indicated concentration. Following the peptide 
incubation for 1 h cells were washed twice with PBS, detached using 5 mM EDTA in 
PBS (15 min at 37 °C), transferred into a tube and spun down. The cell pellet was 
then lysed in 200 µl NP-40 lysis buffer containing a protease inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany). These lysates were sonicated and centrifuged 
for 10 min at 4 °C and 14,000 rpm. Fluorescence emission spectra of the 
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supernatants were recorded immediately (excitation at 492 nm) and fluorescence 
emission ratios (520nm/585 nm) were calculated. 
In the cases of the digestion of the lysate with proteinase K (Figure 3A), four wells 
of a 12 well plate were incubated with the R9-CatD-substrate as indicated. Two of 
four obtained cell pellets were lysed in protease inhibitor containing NP-40 lysis 
buffer as indicated above and fluorescence emission spectra of the two lysates were 
recorded (excitation at 492 nm). The other two cell pellets were lysed in NP-40 lysis 
buffer without protease inhibitors and lysates were prepared. Those lysates were 
subsequently digested with 0.1 mg/ml proteinase K for 16 h. 
 
2.19 Confocal laser scanning microscopy (CLSM) 
CLSM was performed on an inverted LSM510 laser scanning microscope (Carl 
Zeiss, Göttingen, Germany) fitted with a Plan-Apochromat 63x 1.4 N.A. lens. All 
measurements were performed with living, non-fixed cells. 
HeLa cells were seeded at a density of 50,000/well in eight-well chambered cover 
glasses (Nunc, Wiesbaden, Germany). One day later cells were washed once with 
serum-free medium. AlexaFluor 633-Transferrin (Molecular Probes, Eugene, USA) 
and R9-CatD-substrate were added as indicated in serum-free medium. After 30 min 
incubation with the R9-CatD-substrate and AlexaFluor 633-Transferrin, images were 
acquired immediately at RT with peptide and transferrin in the medium. 
For triple detection of fluorescein, Tamra and AlexaFluor 633, a 488 nm Argon-ion 
laser, a 543 nm Helium/Neon and a 633 nm Helium/Neon laser were used for 
excitation in combination with a filter set containing an HFT UV/488/543/633 beam 
splitter. For fluorescein detection a BP 505-530 detection filter was applied, for 
Tamra detection a BP 560-615 detection filter, and a LP650 long pass filter for 
AlexaFluor 633 detection. To avoid cross-talk detection, the multi-track modality of 
the LSM was employed for image acquisition. The AlexaFluor 633 channel was 
virtually free of cross-talk from the other two fluorophores as determined from control 
samples loaded with the R9-CatD-substrate. 
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3.1 Intention 
For cellbiological investigations, for the discovery of specific inhibitors or for 
clinical diagnostics it is necessary to have a fast and reproducible assay for the 
parallel testing of the proteolytic activity of CatD. Previously, several methods have 
been described for measuring the activity of aspartic proteases [Folin & Ciocalteau 
1927, Anson 1938, Dunn et al. 1986, Filippova et al. 1996, Gulnik et al. 1997, 
Yasuda et al. 1999]. A very common method using natural protein substrates like 
bovine hemoglobin is rather time consuming and lacks of specificity [Anson 1939]. 
The generated trichloroacetic acid soluble cleavage products of hemoglobin are 
measured at 280 nm or the tyrosine and tryptophane content is determined using the 
phenol reagent of Folin and Ciocalteau [Folin & Ciocalteau 1927]. A faster method 
uses substrates containing a chromophore, such as a nitrophenylalanine residue, at 
position P1’. Product formation can be measured by monitoring the increase of 
absorbance at 300-310 nm by UV spectroscopy [Dunn et al. 1986]. Recently, 
fluorogenic substrates containing fluorophore and quencher groups like o-
aminobenzoic acid and p-nitroanilide [Filippova et al. 1996] or 5-[(2-
aminomethyl)amino]naphthalene-1-sulfonic acid) (EDANS) and 4’-
dimethylaminoazobenzene-4-carboxylic acid (DABCYL) [Gulnik et al. 1997, 
Matayoshi et al. 1990] within the same molecule have been developed. Upon 
cleavage of the peptide the fluorescence signal is no longer quenched and its 
increase can be measured continuously [Yaron et al. 1979]. 
Here we describe the synthesis of simultaneously fluorophore and biotin labelled 
decapeptide amide substrates and their application to a novel heterogeneous bead-
assay for the determination of CatD activitiy. This method is applied to biological 
samples to analyse CatD activity in endosomal and lysosomal compartments as well 
as in cell lysates of human EBV-transformed B cells and human monocytes. 
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3.2 Results 
3.2.1 Synthesis of biotinylated and fluorescent CatD substrates 
The substrate I was designed based on the published CatD peptide substrate 
KPILFÈFRL. Within this substrate the Phe-Phe bond is predominantly cleaved by 
CatD as previously described by Scarborough et al. 1993. We modified this 
substrate for our digest & pull down assay system by including the two charged 
amino acids glutamic acid and aspartic acid (Table 2) at the N-terminus in order to 
increase solubility. At the C-terminus a glycine residue was introduced as a spacer 
and a lysine residue for the conjugation of the biotin moiety via its ε-amino-group. 
This was achieved by using a Rink amide resin carrying an ε-biotinylated lysine 
residue (Fig. 2). The peptide substrate then was synthesised by elongation via SPPS 
on the lysine’s α-amino-group. After SPPS the substrate was then N-terminally 
labelled with the pH-insensitive fluorophore Amca due to the fact that the assay will 
be performed in an acidic buffer system because CatD has a pH optimum at 3.5 – 
4.0 [Yasuda et al. 1999]. After deprotection and cleavage from the resin the peptide 
amides were purified by preparative RP-HPLC and checked for their correct masses 
using ESI-MS. Peptide purities were determined via analytical RP-HPLC and proved 
to be higher than 97 %. 
 
Table 2 Proteolytic fragments obtained after digesting substrate I, II and III with CatD 
as determined with mass spectrometry. P1 and P1’ residues are shown in 
bold. 
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Figure 2 Synthesis of the biotinylated and fluorescent peptide amide Amca-
EDKPILFFRLGK(biotin)-CONH2. (A) Coupling of Fmoc-Lys(biotin)-OH to Rink 
amide resine. (B) Capping of the remaining amino-groups by acetylation. (C) 
Solid-phase peptide synthesis. (D) Introduction of the fluorophor Amca at the 
N-terminus. (E) Cleavage of the peptide from the resin and side chain 
deprotection 
 
3.2.2 In vitro digestion and optimisation of the peptide substrate 
Substrate I was digested in vitro with CatD and the generated peptide fragments 
were separated using RP-HPLC (Fig. 3, panel A) and identified by MALDI-MS (Table 
2). Substrate I did not posses just one single cleavage site for CatD and was cleaved 
between IÈL, LÈF and FÈF (Table 2, entry I). However, the development of a 
specific CatD assay preferably requires a substrate possessing one single cleavage 
site. Therefore we replaced the hydrophobic amino acid residue leucine in P2 
position with the Acm-protected cysteine derivative Cys(Acm) (substrate II) or the 
hydrophilic amino acid serine (substrate III), respectively. The peptide amide 
substrates II and III were synthesised as described in the experimental section and 
peptide purities were determined using analytical RP-HPLC and proved to be higher 
than 97 %. Substrate II and III were also digested with CatD and the generated 
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peptide fragments were separated by RP-HPLC and identified by MALDI-MS. Both 
substrates were only cleaved between the two phenylalanine residues yielding 2 
peptide fragments (Table 2, entries II and III). No further digestion products were 
observed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 RP-HPLC profiles of substrates I-III after incubation with CatD at pH 3.5 in 50 
mM Glycin-HCl buffer with (upper line) or without (lower line) 10 µM Pepstatin 
using fluorescence detection (λEx. = 350 nm, λEm. = 450 nm). (A) Digestion of 
substrate I with CatD leads to at least 6 determined cleavage products. 
Substrate II (B) and III (C) show only one cleavage site for CatD. 
 
These results suggest that CatD preferable cleaves peptide substrates between 
uncharged and hydrophobic amino acids according to previous published data 
[Scarborough et al. 1993]. Replacement of the uncharged hydrophobic amino acid 
leucine at P2 position renders the substrates II and III to more specific substrates 
which make them attractive tools for the development of a specific CatD assay. 
 
3.2.3 Kinetic characteristics of the developed CatD substrates 
Next we characterised substrates I, II and III with respect to their kinetic properties 
by measuring the initial velocities at various substrate concentrations using analytical 
RP-HPLC with fluorescence detection for the quantification of proteolytic activity. In 
order to obtain data that can be used for kinetic analysis, we tested in which time 
frame the initial velocity is linear (Fig. 4). Within the first 10 min the initial velocity is 
linear and the obtained parameters could be used for Lineweaver-Burk analysis as 
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described in the experimental section. The obtained Km, kcat and kcat/ Km values of 
the substrates I, II and III are listed in Table 3.  
 
 
 
 
 
 
 
 
 
Figure 4 Time courses of the hydrolysis of 10.5 µM substrate I, II and III with 6.5 nM 
CatD in 50 mM Gly/HCl buffer (pH 3.5). The amount of digestion product (DP) 
was determined using RP-HPLC with fluorescence detection as described in 
the experimental section. The hatched area indicates the linear phase of the 
hydrolysis (0 - 10 min). In the presence of 10 µM pepstatin A CatD was 
completely inhibited. 
 
The determined kinetic parameters for the substrates are slightly higher than 
described for previously published substrates [Scarborough et al. 1993, Gulnik et al. 
1997, Yasuda et al. 1999]. Conjugation with biotin and Amca as well as the 
replacement of the hydrophobic amino acid leucine in P2 position leads to a small 
increase of the Km values. As expected substrate I exhibits the lowest Km value due 
to the fact that it possesses several cleavage sites for CatD. Substrate III is more 
specific than substrate I and has a smaller Km value than substrate II and therefore 
proved to be the most suitable substrate for a rapid and specific substrate-based 
CatD assay. Therefore substrate III was used for further experiments. 
 
Table 3 Kinetic parameters for the hydrolysis of the synthesised fluorescent substrates 
I, II and III by CatD. P1 and P1’residues are shown in bold. 
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3.2.4 Application of the substrates for the determination of CatD 
activity 
Figure 6 shows the principle of our novel digestion & pull down assay. After 
incomplete digestion of the substrate III the following peptides are in solution: intact 
substrate and both, fluorescent and biotinylated digestion products. First total 
fluorescence of the reaction solution is measured at an emission wavelength of 465 
nm with excitation at 360 nm immediately after digestion. The obtained value is 
called F1 and represents the total amount of fluorescent peptides in solution i.e. 
digested and undigested fluorescent substrate. In the next step all biotinylated 
peptides are removed using streptavidin-coated magnetic beads, leaving only 
fluorescent digestion products in solution. Then the remaining fluorescence is 
measured yielding the value F2. 
  
 
 
 
 
 
 
Figure 5 Characterisation of the streptavidin-coated magnetic beads. (A) Binding 
capacity of the streptavidin-coated magnetic beads. (B) Time course of the 
conjugation of biotinylated peptide substrate III to 2 µl of the streptavidin-
coated magnetic beads. 
 
Under the conditions described in the experimental section about 95 % of all 
biotinylated molecules are bound and removed (Fig. 5A) from the solution within 10 
min (Fig. 5B). Longer incubation times or the application of more magnetic beads do 
not improve the efficiency of the removal of the biotinylated peptides. The difference 
between the values F1 and F2 coincides proportionally with the amount of digested 
substrate. Using equation 2 shown in the experimental section, the concentration of 
the digestion product (DP) after the appropriate time can be calculated. 
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Figure 6 Principle of the digest & pull down assay: (A) Incomplete digestion of peptide 
substrate and fluorescence measurement (F1). (B) Capturing of biotinylated 
digestion products with streptavidin-coated magnetic beads. (C) Measurement 
of fluorescence (F2) after separation of magnetic beads with a permanent 
magnet 
 
Determination of absolute CatD activity in biological samples requires a calibration 
curve. For this purpose substrate III was incubated with different amounts of CatD in 
the range from 15 mU/ml to 45 mU/ml (Fig. 7). The obtained values were 
interpolated leading to the following equation 
[ ]
1656.0×= t
DPCatD   (equation 3) 
where [DP] is the concentration of the digestion product in µmol/l, t is the digestion 
time in min and CatD is the enzyme activity in mU/ml. The constant factor 0.1656 
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represents the slope of the calibration curve. One unit is defined as the increase in 
the absorbance at 280 nm of 1.0 in 30 min at pH 3.3 and at 37 °C measured as 
trichloroacetic acid soluble products using acid-denaturated hemoglobin as substrate 
(Sigma-Aldrich, Taufkirchen, Germany). 
 
 
 
 
 
 
 
Figure 7 Calibration curve for the determination of CatD activity using the bead-assay. 
Varying concentrations of CatD were incubated with substrate III (10.6 µM) in 
50 µl 50 mM Gly/HCl buffer (pH 3.5) at 37 °C for 10 min. Values represent the 
mean of at least three independent experiments 
 
3.2.5 Determination of CatD activity in subcellular compartments 
of human B cells and monocytes 
To demonstrate the applicability of the digest & pull down assay for biological 
samples the distribution of CatD in different subcellular fractions of the human EBV-
transformed B cell line Boleth and the human monocyte cell line U937 was analysed. 
The two cell lines were selected because of their different CatD expression levels. 
The cell line U937 exhibits a very high level of CatD compared to the Boleth cell line 
where no CatD was detectable in cell lysates using western blot analysis [Greiner et 
al. 2003]. 
In order to validate the versatility of our novel digest & pull down assay for cellular 
CatD activity measurements we compared it with standard western blot analysis. 
Therefore the two cell lines were homogenized and fractionated as previously 
described [Schröter et al. 1999] yielding the following subcellular fractions: crude cell 
extract (CCE), endosomal fraction (E) and lysosomal fraction (L). The total amount of 
protein of each fraction was determined using the method of Bradford [Bradford 
1976]. 15 µg total protein of the subcellular fractions were applied to a 15 % SDS-
polyacrylamide gel and the proteins then were transferred to a PVDF-membrane 
followed by western blot analysis using a rabbit anti-CatD (human) antibody (Fig. 
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8A). Lanes 1, 2 and 3 and 5, 6, 7 represent lysosomal fraction, endosomal fraction or 
crude cell extract of the Boleth cell line and U937 cell line, respectively. Human CatD 
was used as a positive control and is shown in lane 4. The band migrating at 31 kDa 
represents the active mature form of CatD. Two weaker bands at 44 kDa and 51-55 
kDa stand for the intermediate single chain form of CatD and for glycosylated 
proforms of CatD respectively [Rijnboutt et al. 1992]. The control human CatD shows 
a major band at 31 kDa and a small amount of the intermediate single chain form 
and the proform of CatD due to the fact that it has been isolated from human liver. 
In the endosomal fraction and in crude cell extracts of the Boleth cell line no CatD 
could be detected. The band visible in crude cell extract and in the lysosomal fraction 
of the Boleth cell line migrating at 33 kDa is not mature CatD due to the fact that it 
migrates above the mature CatD band. This CatD form has not been identified by 
anyone until now. Only in the lysosomal fraction of the Boleth cell line a small 
amount of mature CatD as well as the intermediate single chain CatD and the 
proform of CatD could be detected. 
In contrast to this intracellular CatD distribution in the Boleth cell line, in all 
fractions of the U937 cell line almost the same amount of mature CatD was detected. 
The single chain intermediate form of CatD is predominantly found in endosomal 
fraction and to a smaller amount in lysosomal fraction and crude cell extract. 
Now the two cell lines were analysed for their CatD activity using substrate III and 
our novel digest & pull down assay. The digest & pull down assay was performed 
with 0.5 µg total protein of the subcellular fraction. The digestion products were then 
separated by RP-HPLC and identified by MALDI-MS. Substrate III was only cleaved 
between the two phenylalanine residues and no further cleavage sites were 
observed when using the inhibitor mix described in the experimental section (data 
not shown). These findings proved that substrate III can be used for specific 
determination of CatD in subcellular fractions of human B cells and human 
monocytes respectively. 
Substrate III was also incubated for 10 min with the subcellular fractions and 
analysed using a microplate reader at an emission wavelengths of 465 nm with 
excitation at 360 nm obtaining F1 and F2 respectively. The amount of digestion 
product in µmol/l was calculated using equation 2. For the determination of the 
absolute CatD activity in the subcellular fractions the obtained amount of digestion 
product was inserted in equation 3 yielding the absolute CatD activity in mU/ml 
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sample volume. The results are shown in Figure 8B and represent the mean of at 
least 3 different experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 (A) Distribution of CatD in subcellular fractions of human EBV-transformed B 
cells and human monocytes (U937) detected by western blot analysis: 52 ng 
of hCatD was used as a positive control and shows a signal at 31 kDa 
(mature CatD) and at 51-55 kDa (proCatD). In all fractions of U937 and in the 
lysosomal fraction of Boleth cells the 31 kDa-mature CatD band is visible. The 
intermediate single chain form of CatD migrating at 44 kDa could only be 
detected in U937. (B) CatD activity in mU/ml as determined by the bead-
assay using the calibration curve shown in figure 6 (L, lysosomal fraction; E, 
endosomal fraction; CCE, crude cell extract) 
 
In the endosomal fraction and in the crude cell extract of the Boleth cell line no 
CatD activity could be detected. Only weak CatD activity was measured in the 
lysosomal fraction. These results concerning the distribution of CatD in subcellular 
compartments agree well with those obtained by western blot analysis. 
As previously described the U937 cell line exhibits a higher CatD expression level 
[Greiner et al. 2003] corresponding to the results obtained with the digest & pull 
down CatD assay. We found an about 40-fold higher CatD activity in the fractions of 
the U937 cell line compared to the Boleth cell line. Another difference between these 
two cell lines is the intracellular distribution of CatD. The lysosomal fraction of U937 
shows an about 20 % higher CatD activity than the endosomal fraction whereas 
CatD in the Boleth cell line could only be detected in the lysosomal fraction and not 
in endosomal fractions. Furthermore the crude cell extract of the U937 cell line 
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exhibits almost the same CatD activity as the lysosomal fraction of U937. These 
results suggest that CatD maybe only slightly enriched in lysosomal fractions and 
otherwise more ubiquitary distributed in the human monocyte cell line U937. 
The developed digest & pull down assay proved to be suitable for determination of 
CatD activity in biological samples. The measured activity using substrate III is 
specific for CatD under the described conditions since there was no other cleavage 
site observed. 
 
3.3 Discussion 
This contribution describes a robust and specific method for the determination of 
CatD activity in biological samples. We present the solid-phase synthesis and in vitro 
digestion of biotinylated fluorescent CatD substrates and their application to a novel 
digest & pull down assay. The CatD digest & pull down assay presented here is 
based on the CatD-mediated cleavage of peptidic substrates bearing a fluorophore 
at their N-terminus and a biotin moiety at their C-terminus. The biotin tag and the 
fluorophore are separated upon digestion with CatD. Subsequent removal of all 
biotin-carrying peptides from the assay solution using streptavidin-coated magnetic 
beads leaves only digested fluorescent substrate in solution. From this amount of 
fluorescent peptide the enzymatic activity of CatD can easily be determined. 
The digest & pull down assay offers several advantages over other state-of-the-art 
protease assays. Commercially available sensitive assays (Amersham Biosciences, 
Freiburg, Germany) are based on the application of substrates bearing two different 
fluorophores. The synthesis of such doubly-labelled fluorescent peptides goes 
beyond standard SPPS [Hoogerhout et al. 1999, Fischer et al. 2003]. Moreover 
many fluorescent dyes used for these substrates are reasonable expensive in 
milligram quantities which clearly limits their broad applicability in straightforward 
solid-phase synthesis, which routinely requires high molar excesses. The choice of 
the two fluorescent dyes for these substrates needs to be evaluated carefully since 
the two different fluorophores can either undergo FRET or quench each other 
significantly [Wei et al. 1994]. 
Another commercially available CatD assay (Molecular Probes, EnzChek™ 
protease assay kit, Leiden, the Netherlands) is based on casein derivatives that are 
labelled with many fluorescent dyes, resulting in almost total quenching of the 
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conjugate’s fluorescence because of the high density of fluorophores within the 
casein protein. After cleavage of the fluorescent casein the quenching of the dyes is 
abolished and the net fluorescence increases significantly [Jones et al. 1997]. 
However, this system lacks specificity since there are lot of potential cleavage sites 
in casein for other proteases. 
The presented digest & pull down assay proved to be more specific for CatD since 
substrate III was only cleaved between the two phenylalanine residues by reaction 
with the subcellular fractions. Another advantage of the digest & pull down assay 
over the assays using quenched peptide substrates is, that a change of the 
fluorescence signal can only result from cleavage of the substrate and not from 
conformational changes of the peptide backbone e.g. caused by binding to another 
protein contained in the sample. 
In the digest & pull down assay described here, short incubation times were 
selected for a fast assay performance. In order to increase the assay’s sensitivity 
longer incubation times may also be applied. The described synthesis of fluorescent 
peptide substrates is simple and can easily be transferred to peptide substrates of 
other proteases and would clearly extend the applicability of this digest & pull down 
assay. Moreover other pH-stable fluorescent dyes, such as rhodamine derivatives, 
may be used for N-terminal labelling of the protease substrates and thus increase 
the sensitivity of the digest & pull down assay due to higher quantum yields. 
For technical applications and high-throughput screening the digest & pull down 
assay can be performed in 96-well plates. All steps including enzymatic hydrolysis, 
removal of biotinylated peptides using the streptavidin-coated magnetic beads and 
fluorescence measurements can be realised in parallel and performed in the 96-well 
plate format. This option underlines that the digest & pull down assay offers a fast 
alternative to other commercially available assays. 
 
3.4 Supplemental data 
3.4.1 Distribution of Cathepsin D in different human cells 
The described digest and pull down assay was additionally applied to determine 
CatD activity in different human PBMCs (peripheral blood monocyte cells). Therefore 
human PBMCs were isolated from buffy coats of donor blood. Subpopulations of B-
lymphocytes, monocytes, granulocytes, and T-cells were positively selected by 
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MACS technique (Miltenyi Biotec, Bergisch Gladbach, Germany) using CD 19, CD 
14, CD 15 and CD 3 antibodies, respectively. Immature dendritic cells were 
generated from CD 14 positiv monocytes which have been isolated using Miltenyi 
Beads after culturing them in IL-4 and GM-CSF containing medium. The CD1c 
positive subform of dendritic cells was directly isolated from human blood. Dendritic 
cells were stimulated for 24 h with lipopolysacharid (LPS), interferon γ (IFNγ) and 
tumor necrosis factor α (TNF-α). 
 
Table 4 CatD Activities in endocytic compartments of different human blood cells. 
 
 
 
 
 
 
 
 
 
 
To determine cathepsin D activity in samples where only a very low amount of 
material is available we analyzed the hydrolysis products by using microbore RP-
HPLC with fluorescence detection. We have been able to measure cathepsin D in 
endocytotic compartments of different human blood cell subpopulations (table 2). 
Endocytic compartments of granulocytes (CD 15) show the smallest amount of 
cathepsin D compared to B-lymphocytes (CD 19), monocytes (CD 14), T-cells (CD 
3) and dendritic cells (DC). The highest cathepsin D activities were measured in 
monocytes and T-cells and are comparable to each other. As previously described 
[Fiebiger et al. 2001] cathepsin D is important for processing of antigens in 
professional antigen-presenting cells (APC) such as DCs. Thus the amount of 
cathepsin D in endocytic compartments of dendritic cells was determined. 
We stimulated dendritic cells with LPS, TNF-α and IFN-γ and determined the 
cathepsin D activities. Stimulated (mature) DCs showed the same cathepsin D 
activity as unstimulated (immature) DCs. These results are in good agreement with 
published data from Trombetta et al. 2003. 
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Further the activity of CatD in lysosomes from resting vs. IFN-γ-stimulated 
microglia as well as astrocytes as a control was tested. CatD showed little variability 
in the presence/absence of IFN-γ both in microglia and astrocytes (Fig. 9). 
 
 
 
 
 
 
 
 
 
Figure 9 Lysosomal extracts from resting vs. IFN-γ-stimulated microglia (MG) was 
assessed for CatD activity. Astrocytes (Astroc.) served as controls and CatD 
activities are expressed in arbitrary units. Mean values and standard deviation 
of triplicate samples are presented (from: Burster et al., 2005). 
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4 Cathepsin D in human eccrine sweat 
4.1 Intention 
The protein pattern of healthy human eccrine sweat was investigated and 10 
major proteins were detected from which apolipoprotein D, lipophilin B and cathepsin 
D (CatD) were identified for the first time in human eccrine sweat. We focused in our 
studies on the function of the aspartate protease CatD in sweat. In vitro digestion 
experiments using a specific fluorescent CatD substrate showed that CatD is 
enzymatically active in human sweat. To identify potential substrates of CatD in 
human eccrine sweat, LL-37 and DCD-1L, two antimicrobial peptides present in 
sweat, were digested in vitro with purified CatD. LL-37 was not significantly digested 
by CatD whereas DCD-1L was cleaved between 44L and 45D and between 29L and 
30E almost completely. The DCD-1L derived peptides generated in vitro by CatD 
were also found in vivo in human sweat as determined by surface-enhanced laser 
desorption/ionization (SELDI) mass spectrometry. Furthermore, besides the CatD 
processed peptides we identified additionally DCD-1L derived peptides which are 
generated upon cleavage with a 1,10-phenanthroline sensitive carboxypeptidase and 
an endoprotease. Taken together proteolytic processing generates 12 DCD-1L 
derived peptides. To elucidate the functional significance of postsecretory processing 
the antimicrobial activity of three CatD processed DCD-1L peptides was tested. 
Whereas two of these peptides showed no activity against gram-positive and gram-
negative bacteria, one DCD-1L derived peptide showed an even higher activity 
against these microorganisms than DCD-1L. Functional analysis indicated that 
proteolytic processing of DCD-1L by CatD in human sweat modulates the innate 
immune defense of human skin. 
Human skin serves as a first line of defense against potential pathogens by 
building a mechanical barrier. In addition to physical mechanisms, the epithelia of 
mammalian skin produce antimicrobial peptides such as cathelicidins [Zanetti et al. 
1995, Nizet et al. 2001] and β-defensins [Harder et al. 1997, Ali et al. 2001] or small 
proteins, such as the recently described 11 kDa S100 protein psoriasin [Glaser et al. 
2005]. Cathelicidins and β-defensins share properties concerning their biosynthesis 
as proforms, which are subsequently processed into mature peptides [Zanetti et al. 
1995, Daher et al. 1988, Valore & Ganz 1992]. During inflammatory conditions such 
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as wound healing [Frohm et al. 1997] or psoriasis [Ong et al. 2002] the expression, 
processing and secretion of the antimicrobial peptides LL-37 [Murakami et al. 2002] 
and β-defensin 1 and 2 [Ali et al. 2001] are increased. As part of the innate defense 
of human skin the antimicrobial peptide dermcidin (DCD) is constitutively expressed 
in eccrine sweat glands, secreted into sweat [Rieg et al. 2004] and present on the 
skin surface at an average concentration of 1 to 10 µg/ml [Schittek et al. 2001]. In 
human sweat the 110 amino acid dermcidin-proform is first processed to the 48 
amino acid peptide DCD-1L. Subsequently DCD-1L is further C-terminally processed 
by a yet unidentified carboxypeptidase [Flad et al. 2002, Rieg et al. 2005]. 
The sole human cathelicidin hCAP-18 is extracellularly processed by proteinase 3 
[Sorensen et al. 2001] to an active 37 amino acid peptide named LL-37 which is 
found in sweat at an average concentration of 0.013 µM [Lopez-Garcia et al. 2005]. 
After secretion LL-37 undergoes further enzymatic processing by an unidentified 
serine protease yielding 3 peptides which enhances the antimicrobial activity of LL-
37 itself [Murakami et al. 2004]. 
Beside these antimicrobial peptides and proteins the surface of human skin 
provides other proteins such as human serum albumin [Nakayashiki 1990], 
cytokeratin I [Langbein et al. 2005], Zn-α-2-glycoprotein [Tada et al. 1991], prolactin-
inducible protein [Myal et al. 1991] and cystatin A [Zeeuwen et al. 2001, Zeeuwen et 
al. 2002]. Additionally certain proteases have been described in human sweat such 
as gelatinolytic and caseinolytic proteases [Horie et al. 1986], cathepsin B- and H-
like cysteine proteases [Yokozeki et al. 1987], human stratum corneum chymotryptic 
enzyme [Kishi et al. 2004] and tissue kallikrein and kininase II [Hibino et al. 1994]. In 
general, the physiological function of these proteins and proteases as well as their 
significance for the immunity of the skin and their interaction with other sweat 
components, especially with antimicrobial peptides, still remains to be determined. 
This contribution presents an overview of the major proteins in human eccrine 
sweat involving 10 dominant proteins. 7 out of these proteins have already been 
described in sweat glands, in sweat or to be secreted by keratinocytes. For the first 
time apolipoprotein D, lipophilin B and CatD (EC 3.4.23.5) were detected and 
identified in human eccrine sweat. 
Furthermore our data show, that CatD takes part in the postsecretory processing 
of the antimicrobial peptide DCD-1L. During these in vitro and in vivo studies we 
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observed two other yet unidentified protease avtivities: a 1,10-phenanthroline 
sensitive carboxypeptidase and an endoprotease which in combination with CatD 
are responsible for the degradation of DCD-1L in sweat yielding 12 DCD-1L derived 
peptides. The antimicrobial activity of three CatD processed DCD-1L peptides was 
tested. Whereas two of these peptides showed no activity against gram-positive and 
gram-negative bacteria, one DCD-peptide showed a higher activity against these 
microorganisms. These data indicate that by postsecretory proteolytic processing the 
antimicrobial activity of DCD-1L is modulated and therefore the immune defense on 
the skin surface. 
 
4.2 Results 
4.2.1 Identification of dominant proteins in human eccrine sweat 
In order to identify dominant proteins in human eccrine sweat standard proteomic 
techniques were applied. In a first step female and male human eccrine sweat 
samples were separated by SDS-PAGE and proteins were stained using Simply 
Blue™ Safe Stain (Fig. 10A). Major protein bands were then excised and digested in-
gel with trypsin. Resulting tryptic peptides were analyzed by MALDI-Re-TOF-MS and 
LC-ESI-MS/MS, respectively. Altogether 10 dominant proteins were identified by 
peptide mass fingerprinting and are listed in Figure 10B. 
We identified human serum albumin (band at 65 kDa) and the antimicrobial 
peptide DCD-1L (bands at 4 kDa) which both have already been described in sweat 
[Nakayashiki 1990, Schittek et al. 2001]. Cytokeratin I (19; 53 kDa) as well as Zn-α-
2-glycoprotein [Tada et al. 1991](38 kDa) and cystatin A [Zeeuwen et al. 2001, 
Zeeuwen 2002](12 kDa) have been described to be present in the duct and 
secretory coil of sweat glands. Myal et al. showed that the prolactin-inducible protein 
(15 kDa) is present in sweat glands [Myal et al. 1991]. Psoriasin has been recently 
identified in keratinocytes [Glaser et al. 2005]. Since psoriasin is secreted by 
keratinocytes in large amounts onto the skin surface it is not surprising that we 
identified this protein also in human sweat. Besides these proteins already described 
to be present in sweat glands or sweat we identified for the first time in eccrine sweat 
apolipoprotein D, lipophilin B and CatD. 
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Figure 10 A) 15% SDS-PAGE of 100 µl desalted and concentrated female and male 
sweat samples. Proteins were stained using Simply Blue™ Safe Stain. B) 
Proteins identified in human eccrine sweat as determined by in-gel tryptic 
digestion followed by mass spectrometry analysis. In certain cases (º) data 
were additionally obtained by automated LC-ESI-MS/MS analysis. All MS data 
were analyzed using Mascot Sequence Query at www.matrixscience.de for 
probability based peptide identification. 
 
4.2.2 The active β-chain of cathepsin D is present in human 
eccrine sweat 
We identified for the first time the β-chain of the aspartate protease CatD in 
human eccrine sweat. The results obtained with tryptic fingerprint analysis were 
proven by Western blot analysis of male (two individuals), female (two individuals) 
and pooled human eccrine sweat. Purified human CatD was used as a positive 
control. Both forms, the active β-chain of CatD (31 kDa) as well as the proform (56 
kDa) could be detected in eccrine sweat, the latter in lower amounts (Fig. 11). We 
did not observe any significant differences between male and female sweat. 
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Figure 11 Western blot analysis of 16 µl female (f1 and f2), male (m1 and m2) and 
pooled (p) human eccrine sweat. Polyclonal rabbit anti-human CatD was used 
as primary antibody and horseradish peroxidase-conjugated goat anti-rabbit 
IgG as secondary antibody. Purified human cathepsin D (human liver) served 
as control and shows a major band at 31 kDa (enzymatically active β-chain) 
and weaker bands at 50 kDa representing several proforms. 
 
Next, we investigated if the β-chain of CatD is enzymatically active in sweat by 
performing in vitro digestion experiments using a specific fluorescent CatD substrate 
as we reported previously [Baechle et al. 2005]. The substrate was incubated for 30 
min with purified CatD or pooled sweat, respectively. Digestion products were then 
separated using analytical RP-HPLC with fluorescence detection (Fig. 12). CatD 
cleaves the substrate Amca-EEKPISFFRLGK specifically between the two 
phenylalanine residues yielding the two peptides Amca-EEKPISF and FRLGK. Only 
the first peptide can be detected using fluorescence detection. The amount of 
generated fluorescent Amca-EEKPISF is proportional to the CatD activity. Figure 
12A shows the undigested CatD substrate with a retention time of 21.7 min. Figure 
12B shows the digestion product Amca-EEKPISF eluting at 20.6 min after digestion 
with purified CatD. In Figure 12C the same sample was measured in presence of the 
metalloprotease inhibitor 1,10-phenanthroline (peak at 11.6 min). The peak areas of 
Amca-EEKPISF in chromatogram B and C are comparable indicating that the 
inhibitor 1,10-phenanthroline has no influence on CatD activity. 
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Figure 12 The CatD substrate Amca-EEKPISFFRLGK was incubated with CatD (B), 
without CatD (A), with CatD and the aspartate protease inhibitor pepstain A 
(C) and with CatD and 1,10-phenanthroline. The substrate further was 
incubated with pooled sweat (D) and with pooled sweat in the presence of 
pepstatin A (E), iodacetamide (F), E-64 (G), leupeptin (H), PMSF (I), EDTA (J) 
and 1,10-phenanthroline (K). Digestion products were then separated using 
RP-HPLC with fluorescence detection (λex=350 nm; λem=450 nm). 
 
After incubation of the substrate with pooled human eccrine sweat Amca-
EEKPISF was generated according to the specificity of CatD (Fig. 12D). This 
cleavage site could be completely inhibited with the aspartate protease inhibitor 
pepstatin A (Fig. 12E), but not with iodacetamide and E-64 (inhibitors for cysteine 
proteases, Fig. 12F and Fig. 12G), leupeptin and PMSF (inhibitors for serine 
proteases, Fig. 12H and Fig. 12I) or EDTA and 1,10-phenanthroline (inhibitors for 
metalloproteases, Fig. 12J and Fig. 12K). These data show, that digestion between 
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the phenylalanine residues is caused by CatD and consequentially that CatD is 
present in its enzymatically active form in human eccrine sweat. 
 
4.2.3 A 1,10-phenanthroline sensitive carboxypeptidase is 
present in human eccrine sweat 
The CatD-substrate is additionally cleaved between serine and phenylalanine 
when incubated with sweat yielding Amca-EEKPIS which has a retention time of 
16.2 min. This finding indicates that another protease is present in sweat. Its activity 
could be completely and specifically inhibited with 1,10-phenanthroline (Fig. 12K) 
showing that the protease is presumably a Zn2+-metalloprotease as the common 
metalloprotease inhibitor EDTA had no effect on the activity (Fig. 12J). Surprisingly 
pepstatin A inhibited both, CatD and the observed cleavage between serine and 
phenylalanine (Fig. 12E). This finding show, that the 1,10-phenanthroline sensitive 
protease cannot cleave the intact substrate until CatD has digested the substrate. 
This suggests that the carboxypeptidase could not cleave the basic amino acid 
lysine but the hydrophobic amino acid phenylalanine. 
To verify this hypothesis the substrate was incubated longer in order to achieve 
additional digestion products which are not generated within 30 min. After 1 h over 
95% of the substrate was cleaved and digestion products were then identified using 
UV-detection and MALDI-MS (data not shown). The peptides Amca-EEKPISF and 
the corresponding peptide FRLGK are initially generated by CatD. Subsequently the 
C-terminally trimmed peptides Amca-EEKPIS, Amca-EEKPI and Amca-EEKP are 
generated but not the corresponding peptides FFRLGK, SFFRLGK and ISFFRLGK 
as would be required for the cleavage by an endopeptidase. These findings show 
that the responsible protease is a carboxypeptidase. 
The intact CatD substrate (lysine at its C-terminus) and Amca-EEKP are not C-
terminally trimmed showing that the 1,10-phenanthroline sensitive protease is a 
carboxypeptidase which releases C-terminal amino acids such as phenylalanine, 
serine and isoleucine but not lysine and proline. 
Our results show that the β-chain of CatD as well as a 1,10-phenanthroline 
sensitive metalloprotease with carboxypeptidase activity are present in their active 
forms in human eccrine sweat. 
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4.2.4 In vitro digestion of the antimicrobial peptides LL-37 and 
DCD-1L with cathepsin D 
Next we investigated whether CatD is able to cleave peptides present in sweat. 
Therefore we incubated the antimicrobial peptides DCD-1L and LL-37 with purified 
CatD and digestion products were then analyzed using RP-HPLC (Fig. 13) followed 
by MALDI-MS of the single fractions (Table 5). These in vitro digestion experiments 
were performed in CatD-buffer (Fig. 13A) and in sweat buffer (Fig. 13B). There were 
no differences for CatD activity detectable between these buffer systems. In both 
buffer systems CatD could be completely inhibited with pepstatin A showing that the 
detected digestion products are exclusively generated by CatD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 In vitro digestion of synthetic DCD-1L and LL-37 with CatD in 50 mM Gly/HCl 
buffer pH 3.5 (A) and in sweat buffer pH 5.5 (B). Digestion products were 
separated using RP-HPLC with UV-detection at 214 nm. Peaks then were 
collected and peptides were analyzed using MALDI-MS and Edman 
microsequencing (see Table 5). 
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DCD-1L (28.66 min) was cleaved by CatD dominantly between 44L and 45D 
yielding SSL-44 (25.58 min) and the tetrapeptide DSVL (9.11 min) and to a lower 
amount between 29L and 30E leading to the peptides SSL-29 (22.96 min) and the 
corresponding peptides ESV-19 (22.50 min) and ESV-15 (16.48 min), respectively. 
These cleavage sites agree well with the specificity of CatD, which preferably 
cleaves proteins and peptides with leucine or an aromatic amino acid residue in P1 
position [van Noort & van der Drift 1989]. 
LL-37 (31.18 min) was also digested with purified CatD but only weak cleavage 
was observed between 5F and 6F yielding FRK-32 (28.16 min) and between 27F and 
28L yielding LRN-10 (13.08 min) and LLG-27 (25.36 min). Taken together, DCD-1L 
proved to be a good substrate for CatD (more than 60 % degradation) whereas LL-
37 is barely digested by CatD (less than 20 % degradation) under the same 
experimental conditions. These results agree well with recently published data, 
stating that LL-37 is processed by a serine protease and not by an aspartate 
protease like CatD [Murakami et al. 2004]. 
 
Table 5 Identified peptides after in vitro digestion of DCD-1L and LL-37 with cathepsin 
D as determined by MALDI-MS and Edman microsequencing. Retention times 
allude to those in figure 14. 
 
 
 
 
 
 
 
 
 
 
Since CatD shows almost no reaction with LL-37 further studies concerning the 
function of CatD in human eccrine sweat focused on DCD-1L. The CatD generated 
DCD-1L derived peptides as well as intact DCD-1L are further processed by the 
above described 1,10-phenanthroline sensitive carboxypeptidase causing a 
successive release of C-terminal amino acids. As a consequence of these in vitro 
results, in vivo investigations were made to find out if one or more of these predicted 
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peptides upon cleavage with CatD and/or the carboxypeptidase are present in 
human eccrine sweat. 
 
4.2.5 In vivo detection of DCD-1L derived peptides in human 
eccrine sweat 
The following DCD-1L derived peptides were found after in vitro digestion of DCD-
1L with CatD: SSL-29, SSL-44, ESV-19, ESV 15 and DSVL (Table 5). These DCD-
1L derived peptides could be further processed by the carboxypeptidase and lack 
one or more C-terminal amino acids leading to a bigger set of predicted DCD-1L 
derived peptides. Now we investigated if one or more of these DCD-1L peptides are 
present in human eccrine sweat. For their detection, sweat samples of 18 healthy 
individuals were applied to SELDI Protein Chip® Technology using reversed-phase 
(H4) chips. Figure 14 shows a representative SELDI-spectrum of sweat in the mass 
range between 2000 Da and 5000 Da. The expected and found molecular masses 
are assigned to the different processed DCD-1L derived peptides seen in the SELDI-
spectrum and are listed in Table 6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 In vivo detection of DCD-1L derived peptides in human eccrine sweat using 
SELDI protein chip® technology. 1 µl sweat was diluted into 2 µl binding buffer 
(50 mM sodium phosphate pH 6.5) and applied to a reversed phase (H4) chip 
surface for 30 min in a humid chamber. After washing three times with binding 
buffer and a final water wash, peptide masses then were read directly from 
the array surface using a ProteinChip reader. 
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Altogether we identified 12 DCD-1L derived peptides in sweat in agreement with 
recently published data [Rieg et al. 2005]. The DCD-1L peptides in sweat agree well 
with our in vitro prediction for the processing of DCD-1L. In addition, peptides lacking 
of the N-terminal tripeptide SSL have been identified. Further enzymatically 
specification of postsecretory processing was achieved by kinetic measurements. 
 
Table 6 DCD-1L derived peptides present in human eccrine sweat and their 
theoretical isoelectric points (pI’s). Asterisks (*) indicate the DCD-1L derived 
peptides generated upon cleavage with cathepsin D. 
 
 
 
 
 
 
 
 
 
 
4.2.6 Temporal order of the postsecretory processing 
Sweat was analyzed at various time points after secretion using SELDI-MS to 
elucidate the temporal order of the postsecretory processing steps. Initially the 48 
amino acid peptide DCD-1L is processed from its C-terminus into the peptide DCD-1 
agreeing with our in vitro results that a carboxypeptidase is active in human sweat. 
This initial processing step starts immediately after secretion of DCD-1L into sweat 
and therefore is experimental difficult to detect. Since harvesting measurable 
amounts of sweat takes time the initial processing steps are barely detectable. To 
solve this problem synthetic DCD-1L was spiked to sweat so that the initial cleavage 
steps could be analyzed in detail. The resulting enzyme-substrate ratio decelerated 
the reaction so that longer incubation was needed. After cleavage of C-terminal 
leucine the peptide DCD-1 (4705.3 Da) is further C-terminally processed into SSL-46 
(4606.2 Da). This processing step occurs simultaneously to the N-terminal cleavage 
of SSL since the peptide LEK-44 (4418.0 Da) arises at about the same time (Fig. 
15). 
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Figure 15 50 µl pooled sweat was spiked with 12 µg synthetic DCD-1L and analyzed by 
SELDI protein chip® technology after 1 h (upper lane) and 15 h (lower lane) at 
37 °C. 
 
Figure 16 shows an example for the temporal order of one particular sweat 
sample whereas the initial processing step into DCD-1 is not apparent for the above-
described reason so the time point “0 min” indicates the time point when the sweat 
sample was thawed and set at 37 °C to start the kinetic measurement. 
After the carboxypeptidase has processed DCD-1L into DCD-1 the next 
processing step is further C-terminal trimming in parallel with N-terminal cleavage of 
the tripeptide SSL by an endoprotease. This processing step generates the peptides 
LEK-45, LEK-44, LEK-43, LEK-42 and LEK-41 (Fig. 16, first 4 spectra). 
Cleavage between 44L and 45D can be performed by CatD as well as by 
subsequent cleavage of four C-terminal amino acids by the carboxypeptidase. We 
wanted to find out which of the two proteases is mainly responsible for this 
processing step. Therefore we synthesized the peptide ESV-17 which represents the 
C-terminus of DCD-1L lacking the last C-terminal amino acids leucine and valine. 
ESV-17 showed no reaction with purified CatD in vitro (data not shown) indicating 
that the two amino acids are essential for the cleavage by CatD. This finding shows 
that the C-terminus of DCD-1L is dominantly processed by the carboxypeptidase. 
In a third processing step the previously generated peptides are cleaved between 
29L and 30E by CatD obtaining the peptides LEK-26 and SSL-29 (Figure 16, last 2 
spectra). The two peptides can be generated from all present DCD-1L derived 
peptides in sweat differing only in their N-terminal sequence. 
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Figure 16 SELDI spectra of sweat after the indicated incubation times at 37 °C. 
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The final processing step consists of two reactions which occur in parallel. One 
reaction is the successive cleavage of the C-terminal amino acids leucine and 
aspartic acid of LEK-26 yielding LEK-24 which is stable against further proteolytic 
breakdown. The other reaction is the conversion of SSL-29 into SSL-25. Since the 
intermediate peptides SSL-28, SSL-27 and SSL-26 could not be detected it remains 
unclear whether this proteolytic degradation is also caused by the 1,10-
phenanthroline sensitive carboxypeptidase or by another endoprotease. The peptide 
SSL-25 undergoes no further enzymatic degradation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Temporal order of the postsecretory processing of DCD-1L in sweat. The 
initial processing step is the cleavage of the C-terminal amino acid leucine by 
a 1,10-phenanthroline sensitive carboxypeptidase (A). The second processing 
step is the cleavage between 3L and 4L by an unidentified endoprotease 
simultaneously to further C-terminal trimming steps (B). The generated DCD-
1L derived peptides are finally digested by CatD yielding LEK-26 and SSL-29 
which are processed to LEK-24 and SSL-25, respectively (C). 
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Single processing steps are summarized in Figure 17 considering data of various 
sweat samples and not only those representatively shown in Figure 15 and Figure 
16, respectively. First DCD-1L is converted to DCD-1 by the 1,10-phenanthroline 
sensitive carboxypeptidase (Fig. 17A). In a next step DCD-1 undergoes further C-
terminal trimming simultaneously to the cleavage of the N-terminal tripeptide SSL by 
an endoprotease (Fig. 17B). Since no aminopeptidase activity was detectable using 
the specific substrate H-Leu-AMC (data not shown) this processing step is caused 
by an endoprotease and not by an aminopeptidase. The third processing step is the 
cleavage between 29L and 30E by CatD obtaining the peptides LEK-26 and SSL-29 
which are further processed to the proteolytical stable peptides LEK-24 and SSL-25 
(Fig. 17C). 
 
4.2.7 Antimicrobial activity of the DCD-1L derived peptides 
Antimicrobial peptides such as LL-37 and DCD-1L play an important part in 
establishing a skin defense barrier against microbes and should be considered as an 
integral part of the innate immune system [Murakami et al. 2002, Schittek et al. 2001, 
Murakami et al. 2004]. Therefore the effect of the postsecretory processing on the 
antimicrobial activity of DCD-1L and DCD-1L derived peptides was investigated. 
The above-described postsecretory processing leads to the proteolytic stable 
peptides LEK-24 and SSL-25 which differ from all other DCD-1L derived peptides 
since they are cationic (for pI values see Table 6, last column). Therefore further 
studies focused on these peptides. In addition, the peptide SSL-29 was chosen since 
recently published data showed that SSL-29 is contained in 89% of sweat samples 
analyzed [Rieg et al. 2005]. This indicates that SSL-29 is a quite stable intermediate 
in postsecretory processing. 
In order to elucidate the biological function of the postsecretory processing by 
CatD, the peptides SSL-29, SSL-25 and LEK-24 were tested for their antimicrobial 
activity against E. coli (Fig. 18A) and Staph. aureus (Fig. 18B) and compared to the 
activity of DCD-1L. 
DCD-1L is highly active against E. coli (LC50 = 30 µg/ml) and Staph. aureus (LC50 
= 10 µg/ml). The peptides LEK-24 and SSL-29 were found to have lost the 
antimicrobial activity against these microorganisms. The peptide SSL-25, the most 
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cationic peptide (pI = 9.4) among the DCD-1L derived peptides shows higher activity 
against E. coli and Staph. aureus (LC50 = 7 µg/ml) compared to DCD-1L. 
 
 
 
 
 
 
 
Figure 18 The antimicrobial activity of DCD-1L and DCD-1L derived peptides SSL-29, 
LEK-24 and SSL-25 evaluated by colony-forming units assay against E. coli 
(A) and Staph. aureus (B). 
 
4.3 Discussion 
Altogether we identified 10 dominant proteins in human eccrine sweat from which 
6 proteins (human serum albumin, cytokeratin I, Zn-α-2-glycoprotein, prolactin-
inducible protein, cystatin A, DCD-1L) have already been described in sweat or in 
sweat glands. Psoriasin was recently identified in keratinocytes as a secretory 
antimicrobial protein [Glaser et al. 2005] indicating, that sweat also contains proteins 
secreted by keratinocytes. The proteins apolipoprotein D, lipophilin B and CatD were 
identified for the first time in human eccrine sweat. Their origin, from sweat glands or 
keratinocytes still remains to be determined. The presented sweat protein pattern 
summarizes the dominant proteins in human eccrine sweat and thus provides useful 
information for further investigations concerning skin diseases such as atopic 
dermatitis or psoriasis in which some of the proteins are involved e.g. cytokeratin I 
[Algermissen et al. 1996]. 
The presence of proteases in sweat and their function is barely understood. There 
are only a few proteases described until now, such as the serine proteases tissue 
kallikrein and kininase II Hibino et al. 1994] and the human stratum corneum 
chymotryptic enzyme [Kishi et al. 2004]. Beside these serine proteases Yokozeki et 
al. [Yokozeki et al. 1987] described cysteine proteases in general to be present in 
sweat but without further specifications. Screening studies revealed that sweat also 
contains several gelatinolytic and caseinolytic proteases [Horie et al. 1986]. 
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However, the functional significance of these proteases in sweat is almost 
completely unknown. 
Recently published data show, that a yet unidentified serine protease is 
responsible for the postsecretory processing of LL-37 in sweat [Murakami et al. 
2004] revealing one possible physiological function of sweat proteases. In 
consideration of these results we show that DCD-1L is postsecretory processed into 
12 DCD-1L derived peptides. Additionally the temporal order of the postsecretory 
processing was investigated in more detail. The initial step is the cleavage of the C-
terminal amino acid leucine by a 1,10-phenanthroline sensitive carboxypeptidase 
which has not been described in sweat until know. The data show, that the 1,10-
phenanthroline sensitive carboxypeptidase resembles carboxypeptidase A (EC 
3.4.17.1) concerning their specificity to release C-terminal amino acids such as Leu, 
Val, Phe, Ile, and Ser but little or no action with Arg, Lys, Glu, Asp or Pro [Peterson 
et al. 1976]. Furthermore the sweat carboxypeptidase is inhibited with 1,10-
phenanthroline but not with EDTA indicating that it is presumably a Zn2+-
metalloprotease. The second processing step is the cleavage between 3L and 4L by 
an unidentified endoprotease which occurs simultaneously to further C-terminal 
trimming steps. Afterwards DCD-1L derived peptides are cleaved by CatD between 
29L and 30E leading to the peptides SSL-29 and LEK-26 which are further processed 
yielding the proteolytic stable peptides LEK-24 and SSL-25. These peptides and the 
peptide SSL-29 were tested for their antimicrobial activity to show the physiological 
significance of the postsecretory processing. The peptide SSL-25 is highly active 
against E. coli and Staph. aureus whereas the cleavage products LEK-24 and SSL-
29 loose their antimicrobial activity. 
The biological role of the postsecretory processing of the antimicrobial peptide 
DCD-1L is to modulate the innate immune response of human skin by the generation 
of a set of shortened peptides which differ in their antibacterial activity. CatD, a 1,10-
phenanthroline sensitive carboxypeptidase and at least one endoprotease are 
involved in the postsecretory processing of DCD-1L and therefore modulate the 
immune defense on the skin surface. The described postsecretory immune 
modulation on the skin surface may smoothen the way for new clinical approaches in 
treatment of skin diseases such as psoriasis since CatD is involved in the 
etiopathology of this inflammatory disease [Chen et al. 2000]. 
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Proteases play central roles in many physiological and pathological processes 
such as cell death, cancer and infectious diseases. Posttranslational modifications 
and interactions with other cellular components may affect the proteolytic activity. To 
obtain maximum information about the pathological relevance of a given protease, it 
is therefore required to measure not only the amount and distribution of the enzyme, 
but also its specific activity in living cells. For this purpose activity-based probes 
need to be developed that specifically probe for protease activities in living cells. 
Here, we present a cell-penetrating protease substrate developed to specifically 
probe the activity of the endolysomal protease cathepsin D (CatD) in living cells. The 
R9-CatD-substrate consists of the highly cationic sequence (RRRRRRRRR, R9) 
which has been described as a cell-penetrating peptide [Futaki et al. 2001] and the 
cathepsin D specific peptide substrate EEKPISFFRLGK which is specifically cleaved 
by cathepsin D between the aromatic phenylalanine residues [Baechle et al. 2005] 
(Fig. 19). 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 Principle of the R9-CatD-substrate 
 
The cell-penetrating R9-CatD-substrate was synthesized by a robust and straight-
forward procedure (Fig. 20) which will be generally applicable to a large variety of 
different protease substrates. Efficient endolysosomal targeting was achieved by N-
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terminal elongation of the probe with the cell-penetrating peptide (CPP) nona-
arginine. So far, in spite of several reports on the import of CPPs by endocytosis, the 
application of CPPs as low molecular weight endosomal targeting sequences has 
received only marginal attention. The protease substrate was flanked by two different 
fluorophores – cleavage of the substrate was detected by changes in the efficiency 
of fluorescence resonance energy transfer (FRET). By incubation of cells with 
different protease inhibitors the contribution of individual proteolytic activities and 
especially of CatD to the break-down of the probe in living cells could be determined 
quantitatively (Fig. 19). 
 
5.2 Results and discussion 
DNA microarray analysis and two-dimensional gel electrophoresis have 
revolutionized the analysis of changes in the levels of transcription and translation of 
proteins. However, for enzymes, the levels of transcription and translation, in many 
cases, do not correlate with their activities [Gygi et al. 1999]. Therefore, in order to 
arrive at a functional understanding of molecular networks, the large scale 
approaches for expression analysis have to be complemented by functional 
analyses. Proteases play essential roles in all live cycles of organisms. Given this 
importance, different strategies have been developed for measuring enzyme 
activities. Activity-based probes (ABPs) have been widely used for the analysis of 
cysteine, serine and threonine proteases [Speers & Cravatt 2004]. Especially for 
caspases, proteases essential in the initiation and execution of programmed cell 
death, numerous small and large molecule probes have been presented [Chahroudi 
et al. 2003, Bullok & Piwnica-Worms 2005]. However, many of these protease-
directed ABPs lack specificity. Therefore, especially quantitative information on the 
activity of a particular enzyme is difficult to obtain. Until now lengthy biochemical 
analyses such as SDS-PAGE of cell lysates and identification of proteases bound by 
the ABP are required. 
Ideally, (i) an activity-based probe should provide quantitative information on a 
specific enzymatic activity in living cells, and (ii) the manipulations required for 
processing of samples be minimized enabling such functional analyses in high 
through-put. For a general application in tissue culture, tumor samples and in vivo 
synthetic low molecular weight probes are highly preferable as transfection of cells 
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with genetically encoded enzyme probes imposes severe constraints on the 
experimental design [Harpur et al. 2001]. Finally, the design of these probes should 
be based on a principle that can easily be adapted to different proteases. 
Here, we present a synthetic low molecular probe that efficiently targets the 
endolysosomal compartment for probing the activity of the aspartic protease 
cathepsin D (CatD, EC 3.4.23.5). The aspartic protease CatD possesses major 
physiological and pathophysiological implications. In the control of the immune 
response, CatD is involved in the degradation of proteins and generation of peptides 
presented by MHC class II molecules [Rodriguez & Diment 1992]. Moreover, CatD is 
necessary for the processing of the β-amyloid precursor protein playing a major role 
in Alzheimer's disease [Ladror et al. 1994]. Finally, overexpression of CatD in breast 
cancer cells is associated with an increased risk of metastasis, caused by the CatD-
induced cancer cell proliferation [Glondu et al. 2001]. 
A short doubly-labeled substrate for a fluorescence-based read-out was combined 
with a cell-penetrating peptide (CPP), serving as an endolysosomal targeting 
peptide. Cell-penetrating peptides represent widely used vectors for the import of 
molecules into mammalian cells in basic and applied biomedical research [Fischer et 
al. 2005]. However, to this point, the application of these peptides nearly exlusively 
intended to target molecules into the cytoplasm or nucleus. Recent findings 
demonstrated a role of endocytosis in the uptake of CPPs [Richard et al. 2003]. We 
therefore intended to explore whether these synthetic low molecular weight vectors 
could be used to efficiently target a substrate to lysosome-resident CatD. Because of 
its efficient cellular uptake, nona-arginine was selected as a CPP [Wender et al. 
2000]. 
As a substrate we selected a peptide recently developed in our laboratory 
[Baechle et al. 2005]. This substrate is cleaved efficiently by CatD between the two 
phenylalanine residues. This peptide was N-terminally elongated with nona-arginine. 
Fluorescence resonance energy transfer (FRET) was selected for detecting the 
degradation of the targeted substrate. Site-specific attachment of carboxyfluorescein 
and carboxytetramethylrhodamine to either terminus of the substrate, instead of 
attachment to the termini of the entire peptide, was intended to maximize the 
specificity of this probe for CatD. The design and the synthesis of this targeted 
protease substrate are depicted in Figure 20. 
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Figure 20 Synthesis of the doubly-labeled R9-CatD-substrate (Ac-RRRRRRRRR-
Lys(εTamra)-APISFFELG-εLys(αFluo)-CONH2). The peptide was assembled 
by automated solid-phase peptide synthesis on the free ε-amino group of the 
Nα-carboxyfluorescein(Trt)lysine-preloaded Rink amide resin [Fischer et al. 
2003]. a) Repeated cycles of SPPS, the N-terminal amino group was blocked 
post-synthesis by acetylation b) Removal of the Dde-protecting group c) 
Introduction of the second fluorophore using carboxytetramethylrhodamine-N-
succinimidyl ester d) Cleavage of the peptide amide off the resin and side-
chain deprotection 
 
The synthesis of this molecule was based on a Rink amide-based resin preloaded 
with a lysyl-residue carrying a tritylated carboxyfluorescein (Fluo) at its α-amino 
group that enables the highly efficient synthesis of peptide collections labeled with 
fluorescein at the C-terminus [Fischer et al. 2003]. Following automated synthesis of 
the conjugate, the orthogonal Dde (1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)-
protecting group was removed smoothly [Bycroft et al. 1993]. The free ε-amino group 
of the lysine was derivatized with carboxytetramethylrhodamine (Tamra) using the 
succinimidylester-preactivated fluorophore. The resulting peptide (= R9-CatD-
substrate) was cleaved off the resin and side-chain deprotected. 
The crude peptide amide was obtained at 65% purity (Fig. 21) and was purified for 
further investigations. 
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Figure 21 (A) MALDI-TOF mass spectrum of the crude R9-CatD-substrate, calc. [M+H]+ 
= 3455.0 Da). (B) HPLC elution profile of the crude peptide (purity 70 % (RP-
HPLC, 214 nm)). 
 
Digestion of the peptide with purified human CatD and analysis of the digestion 
products by RP-HPLC and MALDI-MS revealed that the R9-CatD-substrate is 
specifically cleaved between the two phenylalanine residues (Fig. 22). Therefore 
purified R9-CatD-substrate (30 µM) was incubated for 1 h in 50 mM Gly/HCl buffer 
pH 3.5 with 0.65 µM bovine CatD in a volume of 50 µl. The reaction was stopped by 
adding 50 µl of a H2O/ACN/TFA (94:5:1, v/v/v). Digestion products were then 
separated by analytical RP-HPLC with detection at 214 nm. The column was eluted 
at a flow rate of 0.2 ml/min with the following solvent system: (A) 0.055% (v/v) TFA in 
H2O and (B) 0.047% (v/v) TFA in ACN/water (4:1, v/v) using a linear gradient from 
5% B to 80% B within 30 min. The chromatograms are shown in Figure 22A. 
Identified peptides are listed in Figure 22B. 
 
 
 
 
 
 
 
 
 
Figure 22 (A) HPLC elution profile of the purified R9-CatD-substrate (left) and of the 
CatD digested R9-CatD-substrate (right). (B) Identification of the CatD 
digestion products. The two FELGK(Fluo) fragments result from the positional 
isomers of carboxyfluorescein used for the preparation of the Nα-
carboxyfluorescein-labeled lysyl-Rink amide resin [Fischer et al. 2003]. 
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In order to confirm that the R9-CatD-substrate was targeted to endocytic 
compartments we performed live cell confocal fluorescence microscopy (CLSM) of 
HeLa cells incubated with the peptide. The R9-CatD-substrate was taken up 
efficiently (Fig. 23). A high degree of co-localization for the fluorescence of both 
fluorophores attached to the R9-CatD-substrate could be observed within vesicular 
structures. Moreover the vesicular staining of both peptide-derived fluorescence 
signals co-localized with AlexaFluor 633-labeled transferrin, which is internalized by 
clathrin-mediated endocytosis. These microscopy data demonstrate that the R9-
CatD-substrate is internalized by endocytosis and subsequently found in endocytic 
compartments. 
Inside intact cells, the reduction of fluorescein fluorescence by the acidic 
conditions within lysosomes and concentration quenching set a limit to a quantitative 
assessment of the proteolytic break-down using microscopy [Sjöback et al. 1995, 
Chen & Knutson 1988]. For this reason, we complemented the cellular analyses by 
spectral analyses in cell lysates prepared from HeLa cells pulsed with the R9-CatD-
substrate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Endocytic uptake and intracellular localization of the R9-CatD-substrate in 
HeLa cells. HeLa cells were incubated with serum-free medium containing the 
R9-CatD-substrate (2 µM) and AlexaFluor 633-transferrin (25 µg/ml) for 30 
min and were then analyzed by multi-channel CLSM: (A) Fluorescein 
fluorescence, (B) Tamra fluorescence of the substrate, (C) overlay of these 
two channels, (D) AlexaFluor 633-transferrin fluorescence, (E) overlay of all 
three fluorescence channels, (F) transmission. 
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HeLa cells were selected since this cell line has served as a model for 
investigating the internalization of CPPs [Richard et al. 2003, Fittipaldi et al. 2003, 
Console et al. 2003, Potocky et al. 2003, Saalik et al. 2004] and more importantly 
these cells express CatD (Fig. 24) [Deiss et al. 1996, Cirman et al. 2004]. 
 
 
 
 
 
 
 
Figure 24 Western Blot analysis for the validation of the CatD expression in HeLa cells 
(lane 1: 30 ng of purified human CatD, lane 2: 100 µg total protein of HeLa 
cell lysate). 
 
In order to validate this technique for a quantitative determination of break-down 
we recorded fluorescence emission spectra upon excitation at 492 nm after mixing 
different amounts of completely digested and intact R9-CatD-substrate (Fig. 25A). 
 
 
 
 
 
 
 
 
 
Figure 25  (A) A solution containing 100 nM of the R9-CatD-substrate was digested with 
proteinase K. After blocking protease activity by addition of PMSF different 
amounts of this solution and a 100 nM R9-CatD-substrate solution were 
mixed to yield the indicated fractions of digested peptide. The fluorescence 
emission spectra were recorded upon excitation at 492 nm. (B) Ratios of 
fluorescence at 520 nm and 585 nm were calculated from the fluorescence 
emission spectra. All digests and measurements were performed as 
duplicates; error bars represent the absolute deviations from the mean value 
(a.u., arbitraty units). 
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Calculation of ratios of fluorescence at 520 and 585 nm rendered the detection of 
peptide break-down independent of concentration [Takakusa et al. 2002]. Ratios of 
fluorescence emissions ranged from 1.0 to 3.8 and correlated positively with the 
fraction of degraded peptide (Figure 25B). This experiment clearly indicates that for 
the R9-CatD-substrate ratiometric measurements can be used to determine 
quantitatively the degree of proteolytic breakdown. 
 
 
 
 
 
 
 
 
 
 
Figure 26 Fluorescence emission ratios for the determination of proteolytic degradation 
in the endolysosomal pathway. (A) HeLa cells were incubated with the R9-
CatD-substrate (1 µM) for 1 h. (B) HeLa cells were incubated with the R9-
CatD-substrate (1 µM) for 1 h in the absence or presence of different 
inhibitors (300 nM bafilomycin A1, 100 µM chloroquine, 50 µM lactacystin). 
The inhibitors were added 1 h prior to the probe. Each condition was tested in 
duplicate; error bars represent the absolute deviations from the mean value. 
 
For HeLa cell lysates, after a 1 h peptide pulse, a ratio of about 2.0 was measured 
(Fig. 26A). Further treatment of this cell lysate with proteinase K yielded a ratiometric 
value of about 3.6, indicating that in the lysate about 50% of the substrate moiety 
had still been intact. 
We suspected that a significant part of the degradation inside the cell had resulted 
from the activity of other enzymes. As a first step towards a quantitative 
determination of the fraction of probe digested by CatD we therefore investigated 
whether intracellular peptide stability was affected in the presence of inhibitors that 
perturb the activity of proteases inside living cells. A set of three inhibitors was 
selected. Bafilomycin A1 and chloroquine represent widely used inhibitors of 
endosomal acidification and exert an indirect inhibitory effect on endolysosomal 
proteolysis. The bacterial metabolite lactacystin selectively inhibits the 20S 
64 
5 A cell permeable CatD substrate 
proteasome and was selected to block the major protease activity in the cytoplasm. 
For cells pulsed with peptide in the absence of inhibitor, the emission ratio was 2.0. 
Both bafilomycin A1 and chloroquine had a significant effect on the intracellular 
stability of the R9-CatD-substrate. The emission ratios decreased to about 1.0 
(bafilomycin A1) and 1.6 (chloroquine). Lactacystin had a little, albeit reproducible 
effect on the emission ratio (Fig. 26B). These results clearly demonstrate that 
inhibitors can be used to dissect the contributions of proteolytic activities in 
subcellular compartment on the degradation of the R9-CatD-substrate in living cells. 
The proteasome cleaves only a small amount of the internalized peptide whereas the 
endosomal passage and endosome-resident proteases have a major impact on the 
integrity of the probe inside HeLa cells. 
After having determined the contribution of proteases inside the endolysosomal 
compartment on the digestion of the R9-CatD-substrate we next sought to quantify 
the role of individual proteases in this compartment and especially of CatD. Instead 
of inhibitors that exert a general effect on endolysosomal proteases, in this case, 
protease-specific compounds were employed. Pepstatin A was selected as a specific 
inhibitor of CatD and aspartic proteases. In addition the influence of E-64d acting as 
a broad-band irreversible cysteine protease inhibitor was investigated. This chemical 
is commonly used for the inhibition of cysteine proteases involved in endosomal 
degradation. Members of the cysteine protease family make up most of the 
proteases that are present in the endolysosomal compartment. In this case, a 
calibration curve (Fig. 25B) obtained from cell lysates that contained different 
amounts of digested and intact peptide was used to convert the ratiometric values 
into absolute values for the fraction of digested peptide (for detailed description see 
material and methods section). In HeLa cells pepstatin A decreased the amount of 
digested peptide from 30% to 25%, E-64d from 30% to about 15% (Fig. 27). 
Since pepstatin A inhibits CatD as an aspartic protease and E-64d endolysosomal 
cysteine proteases, the inhibitory effect of both drugs should be additive. Indeed the 
amount of digested peptide was diminished to less than 5 % indicating almost 
complete inhibition of intracellular proteolysis by a combination of E-64d and 
pepstatin A. 
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Figure 27 Fraction of the R9-CatD-substrate digested by CatD. HeLa cells were 
incubated with the R9-CatD-substrate (1 µM) for 1 h in serum-free medium in 
the absence or presence of protease inhibitors (100 µM pepstatin A, 40 µM E-
64d or both inhibitors). The inhibitors were added 1 h prior to the substrate. 
Then cells were washed, harvested with EDTA/PBS and lysed. Afterwards 
fluorescence emission spectra were recorded in cell lysates. The percentage 
of digested peptide in cell lysates was calculated based on internal standard 
lysis buffer solutions containing definite amounts of digested and intact 
peptide. Each condition was tested in duplicate and error bars represent the 
absolute deviations from the mean value. 
 
In summary our data clearly show that conjugation of a protease substrate to 
nona-arginine results in a highly efficient targeting of this enzyme probe to the 
endolysosomal compartment. In combination with protease inhibitors, the small 
molecule smart protease probe yielded detailed quantitative information on 
proteolytic activities inside a cell. The concept is highly relevant for pharmaceutical 
applications since it the probe design and assay format are compatible with 
quantitative cellular screening formats. 
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6.1 Intention 
A vast number of applications in bioanalytical chemistry depend on fluorescently 
labeled molecules [Brand & Johnson 1997]. Fluorescein derivatives have evolved to 
widely used reagents for the preparation of hydrolytically stable fluorescent peptide 
and protein conjugates [Weber et al. 1998]. Fluorescein-labeled peptide derivatives 
have been employed as fluorescent markers in bioanalytical applications such as 
confocal laser scanning microscopy [Schmidt et al. 1998] and intracellular 
fluorescence correlation spectroscopy [Waizenegger et al. 2002]. One major 
drawback of this fluorophore apart from the moderate photostability [Song et al. 
1995] is the strong pH-dependence of the fluorescence properties [Sjöback et al. 
1995]. Carboxyfluorescein exhibits bright fluorescence emission in neutral and basic 
buffers. However, under acidic conditions, protonation lowers the fluorescence 
quantum yield, decreases the molar extinction coefficient and shifts the maximum of 
the excitation spectrum towards shorter wavelengths. 
Exploiting either pre- or post-column derivatization procedures, fluorescein has 
been employed for the highly sensitive detection of molecules after chromatographic 
separation [Krull et al. 1997]. However, standard reversed-phase high-performance 
liquid chromatography (RP-HPLC) solvents commonly contain trifluoroacetic acid 
(TFA) as ion-pairing agent. When standard RP-HPLC analysis of fluorescein-labeled 
compounds is combined with fluorescence detection, the acidic pH of TFA drastically 
reduces the sensitivity of the analytical system. Our aim was to develop a method 
that would enable the highly sensitive detection of fluorescein-labeled peptides by 
RP-HPLC, however, would not require a modification of established optimized 
gradient systems. Here we demonstrate that post-column alkalinization of RP-HPLC 
eluates before detection enabled the highly sensitive detection of fluorescein-labeled 
peptides. 
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6.2 Results and discussion 
A commercially available fluorescence-based HPLC-system (Shimadzu, Duisburg, 
Germany) consisting of a system controller (SCL-10A VP), an auto injector (SIL-
10AD VP), two micro-plunger piston pumps (LC-10 AD VP), a UV detector (SPD-
10AV VP) and a fluorescence detector (RF-10A XL) was modified (Fig. 31). Peptides 
were separated on a RP-column (Nucleosil 100, C18, 125×2 mm, 5 µm particle 
diameter) using a binary solvent gradient (solvent (A) 0.055% (v/v) TFA in H2O, 
solvent (B) 0.047% TFA (v/v) in acetonitrile/water (4:1, v/v) with a flow rate of 0.2 
ml/min and a linear gradient from 5% B to 80% B within 40 min. The pH value of both 
solvents approximated 2.5. Post column, the eluate was mixed on-line with an 
aqueous ammonia solution (NH4OH/water, 2.5:100, v/v, pH 11.5) which was 
delivered by another micro-plunger piston pump (L-6200 A, Merck/Hitachi 
(Darmstadt, Germany) with a flow rate of 0.15 ml/min resulting in a pH value of the 
eluate of 10. The flow rate and the concentration of the aqueous ammonia solution 
was optimized so that no mixing chamber was required. Under these conditions no 
loss of reproducibility and peak resolution was observed. Detection was carried out 
using both the UV detector (214 nm) and the fluorescence detector (λex = 490 nm 
and λem = 520 nm). 
To demonstrate the bioanalytical applicability of the post-column alkalinization 
method we selected the cell-penetrating peptide (CPP) penetratin [Derossi et al. 
1994] as a model peptide. Fluorescein represents the most-widely used fluorophore 
for the investigation of the cellular uptake and intracellular routing of CPPs [Fischer 
et al. 2004]. Penetratin (RQIKIWFQNRRMKWKK-COOH) and the non cell-
penetrating control peptide ANDREASDANIEL-COOH were synthesized using 
standard solid-phase peptide synthesis and labeled at their N-termini with the 
fluorophore 5-carboxyfluorescein (Fluo) as described previously [Baechle et al. 
2005]. The crude peptides were purified by preparative RP-HPLC (purities > 95%) 
and the identity of both peptides was confirmed using matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS). 
Twenty fmol Fluo-penetratin (52.1 pg) were separated according to the above 
described procedure and elution profiles were recorded. Using the settings routinely 
used for the detection of fluorescein (λex = 490 nm and λem = 520 nm) [Oefner et al. 
1994], only little signal intensity could be detected in the TFA-containing eluents (Fig. 
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28, chromatogram a). Adjustment of the excitation wavelength to 435 nm, the 
maximum of the absorption spectrum of fluorescein at pH 2.5 [Sjöback et al. 1995], 
yielded a 2.7-fold signal increase compared to chromatogram a). For the same 
sample the above described post-column alkalinization procedure (chromatogram c) 
yielded a 42-fold signal amplification compared to chromatogram a) and a 15-fold 
signal amplification compared to chromatogram b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 Dependence of peak intensities on detection conditions. Detection without 
sample alkalinization with excitation at 490 nm (a) and 435 nm (b) and with 
sample alkalinization and excitation at 490 nm (c). In all cases 20 fmol Fluo-
penetratin (52.1 pg, 2 nM) were loaded onto the column and fluorescence 
detection was carried out at 520 nm. 
 
In order to validate the method for quantification of fluorescein-labeled peptides, 
the response function was recorded for 7 different amounts of Fluo-penetratin 
ranging from 0.2 fmol (0.52 pg) to 40 fmol (104.2 pg). A linear concentration 
dependence (R2=0.99) was obtained for the entire concentration range. The 
detection limit was approximately 0.2 fmol with a signal-to-noise ratio of 5. Fluo-
penetratin eluted at 26.10 min and retention times exhibited an excellent 
reproducibility (relative standard deviation for the retention time: 0.13%). Previously 
published detection limits for post-column derivatization including fluorescein 
isothiocyanate (detection limit: 50 fmol, S/N = 2)[Muramoto et al. 1984], N-
hydroxysuccinimidyl fluorescein-O-acetate (detection limit: 3.2 fmol, S/N = 3) [Wang 
et al. 2000], and 6-oxy-(N-succinimidyl acetate)-9-(2’-methoxycarbonyl)fluorescein 
(detection limit: 2.0 fmol, S/N = 3) [Cao et al. 2005] were 10 to 100 fold higher than 
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the detection limit of our post-column alkalinization method which is 0.2 fmol with a 
signal-to-noise ratio of 5. 
In addition to a strong benefit in sensitivity, fluorescence-based detection is highly 
attractive for the analysis of peptide uptake and break-down in complex biological 
samples. Fluorescence enables the highly specific discrimination of exogeneously 
added CPP’s from endogenous molecules. To demonstrate the applicability of the 
post-column alkalinization RP-HPLC method for biological samples, the two above 
mentioned peptides were compared with respect to their ability to interact with cells. 
Human EBV-transformed B cells (Boleth, IMGT/HLA sequence database number: 
HC10329) were incubated with Fluo-penetratin and Fluo-ANDREASDANIEL. Fluo-
penetratin is described to efficiently associates with the plasma membrane and to be 
internalized into different cell types [Derossi et al. 1994]. For the control peptide 
Fluo-ANDREASDANIEL no such association and internalization were expected. 
B cells were diluted in serum-free RPMI 1640 medium (Gibco, Invitrogen-Gibco, 
Karlsruhe, Germany) and transferred into a 96-well plate (Nunc, Wiesbaden, 
Germany) with 200 µl cell suspension per well (105 cells/well). The two peptides 
were added to a final concentration of 5 µM to the cell suspensions. After 2 h 
incubation at 37 °C cells were washed 5 times with PBS (pH 7.4, Gibco-Invitrogen, 
Karlsruhe, Germany), lysed in 200 µl detergent-containing buffer (0.5% (w/v) 
Zwittergent 3-12 in 50 mM Tris(hydroxymethyl)aminomethane, pH 8.0) and boiled for 
5 min. After removal of cell debris by centrifugation (13000 rpm, 5 min, Heraeus 
Biofuge pico), 50 µl of the supernatants (total volume: 200 µl) were applied to the 
post-column alkalinization RP-HPLC system (Fig. 29). All chromatographic 
measurements were performed as triplicates. The amount of Fluo-penetratin 
(chromatogram a) was more than 10 times greater than that of the control peptide 
Fluo-ANDREASDANIEL (chromatogram b). 
Absolute amounts of cell-associated fluorescence were calculated based on the 
calibration curve (y = 242.91 × x, where y is the peak area and x stands for the 
absolute amount of fluorescein-labeled peptide in fmol) and yielded 117.3 fmol (0.3 
ng, 2.3 nM in 50 µl cell lysate) of Fluo-penetratin and 9.7 fmol (17.2 pg, 0.2 nM in 50 
µl cell lysate) of Fluo-ANDREASDANIEL per 2.5×104 B cells. The total amount of 
Fluo-penetratin eluting at 26.17 min compared to the one of all other fragments 
indicated that only 10% of the internalized CPP had remained intact. These data 
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show that the post-column alkalinization RP-HPLC method can be used for the 
quantification of the cellular internalization of fluorescent cell-penetrating peptides 
and the identification of proteolytic break-down. In addition this approach may be 
combined with off-line MALDI-MS for the identification of degradation products 
[Elmquist & Langel 2003]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 Detection of Fluo-penetratin (a) and Fluo-ANDREASDANIEL (b) in cell 
lysates. B cells (2.5 × 104 B cells) were incubated with the indicated amount of 
the corresponding peptide (5 µM), washed and lysed in 200 µl lysis buffer. 
Subsequently 50 µl of each lysate were subjected to the described separation 
procedure (including post-column alkalinization and fluorescence detection 
(λex = 490 nm and λem = 520 nm). 
 
The presented data clearly demonstrate that our post-column alkalinization RP-
HPLC method strongly enhances the sensitivity of fluorescence detection of 
fluorescein-labeled compounds by more than 40-fold compared to previously 
published protocols. Moreover the method is highly reproducible and suitable for the 
determination of fluorescent peptides in complex cell lysates. The method represents 
a valuable complementation to the analysis of peptide uptake and distribution by flow 
cytometry and fluorescence microscopy [Fischer et al. 2004] as it provides absolute 
quantities and allows the differentiation between degraded and intact fluorescent 
peptides. 
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6.3 Supplemental data 
The following figure illustrates the configuration of the RP-HPLC system for the 
postcolumn alkalinization method. Only an additional pump for the delivery of the 
ammonium hydroxide solution is necessary without a mixing chamber. Optimization 
of the flow rates of the solvents is sufficient for the optimal separation and detection 
of fluorescein-labeled peptides. 
 
 
 
 
 
 
 
 
 
Figure 30 Configuration of the RP-HPLC system for post-column sample alkalinization 
including system controller, auto injector (AI), peristaltic pumps (p), solvent 
degasser (SD), UV detector (D1, 214 nm) and fluorescence detector (D2, λex 
= 490 nm and λem = 520 nm). The samples are separated at pH 2.5, 
alkalinized and detected at pH 10. 
 
The calibration curve stated below points out, that the post-column alkalinization 
method is highly reproducible indicated by the small standard deviation. Furthermore 
the method is suitable for the determination of fluorescein-labeled substances within 
a wide concentration range since the signals (i.e. peak areas) are linear from 0.2 
fmol to 40 fmol (R2 = 0.99) (Fig. 31). 
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Figure 31 Calibration curve for the total amount of Fluo-penetratin (fmol) determined 
using the postcolumn alkalinization procedures followed by peak integration. 
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Recently the uptake of different CPPs (penetratin [Derossi et al. 1994], pVEC 
(LLIILRRRIRKQAHAHSK) [Säälik et al. 2004] and (KFF)3K [Petersen et al. 2004]) in 
two yeast species, Saccharomyces cerevisiae and Candida albicans, was studied 
using fluorescence HPLC-analyses of cell content whereas the intracellular 
degradation of the CPPs varies from complete stability to complete degradation 
according to our results [Holm et al. 2005]. 
Moreover the described postcolumn alkalinization procedure was applied for the 
detection of the peptide inhibitor D-JNKI-1 for the c-Jun N-terminal Kinase (EC 
2.7.1.37) in cooperation with the Hearing Research Center Tübingen. Results were 
part of the final report within a research project financially supported by the 
University Hospital Tübingen (fortüne project 1309-0-0). The peptide was conjugated 
to Tat and labelled with FITC. Continuous local application of the peptide to the 
guinea pig cochlea yielded only low signal intensities due to the different membrane 
structure of the cochlea compared to, for example, HeLa cells or EBV-transformed B 
cells. 
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7.1 Abstract 
The specific and sensitive detection of protease activities within aqueous 
biological fluids such as blood, urine, sweat or cell lysates is important since 
proteases are widely used biomarkers for the discrimination between diseased and 
healthy samples. Recently, great efforts have been made to develop new proteomic 
approaches implying screening studies for the parallel determination of various 
parameters. Therefore specific and high-throughput compatible methods are 
required. The present work describes a new method for the determination of CatD 
activity which is generally applicable on peptide substrates and represents a useful 
tool and complements established enzyme assays. The applicability of the digest & 
pull down assay was applied to biological samples such as cell lysates and sweat. 
As a result thereof, CatD was detected in human eccrine sweat. Furthermore, we 
could show that CatD, in combination with at least two other proteases, is involved in 
the postsecretory processing of the antimicrobial peptide DCD-1L into 12 DCD-1L 
derived peptides from which at least one (SSL-25) shows an higher activity than 
DCD-1L. Thus postsecretory processing by CatD modulates the innate immune 
defense of human skin by generating a bigger set of DCD-1L derived peptides with 
different antimicrobial activities. 
Recently, fluorescence based visualization techniques such as confocal laser 
scanning microscopy (CLSM) and fluorescence associated cell sorting (FACS) more 
and more became the methods of choice for cellular investigations. So it is highly 
desirable to develop innovative fluorescent probes which are compatible to these 
bioanalytical methods. Since protease activities commonly can only be detected in 
cell lysates a new cell permeable peptide substrate was designed for the 
visualization of protease activity within living cells. The developed R9-CatD-substrate 
consists of the cell-penetrating peptide R9 and the specific CatD-substrate. The 
scissile bond is flanked by TAMRA and carboxyfluorescein respectively. Upon 
cleavage with CatD the quenching of the fluorophores is abolished and both the 
TAMRA and the carboxyfluorescein fluorescence can be measured. Once in the 
endolysosomal pathway the R9-substrate is cleaved and the fluorescence increases 
as can be determined by CLSM and FACS analysis. The presented design of cell-
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penetrating, doubly-labeled peptide substrates and their application for cellular 
investigations is an innovative and promising approach which reasonably endorses 
other common techniques such as in vitro digestion experiments or western blot 
analysis. 
As already mentionend above, a vast number of applications in bioanalytical 
chemistry depend on fluorescein labeled molecules. Fluorescein derivatives have 
evolved to widely used reagents for the preparation of hydrolytically stable 
fluorescent peptide and protein conjugates. However, the strong pH dependence of 
the fluorophore narrows its applicability especially in acidic buffer systems such as it 
is the case for commonly used RP-HPLC systems. Therefore a new RP-HPLC 
method was developed yielding a 40-fold signal increase without loss of 
reproducibility or peak resolution. This method has been used for the quantification 
of cellular uptake of the fluorescent labeled cell-penetrating peptide penetratin by 
human EBV-transformed B cells. 
Taken together, a new method for the determination of CatD activity based on 
biotinylated and fluorescent peptide substrates was developed and applied to 
various biological samples particularly to human eccrine sweat, where CatD could be 
detected for the first time. In this context the physiological function of CatD in human 
eccrine sweat was investigated stating its involvement in the postsecretory 
processing of the antimicrobial peptide DCD-1L and therefore its role in the 
modulation of the immune defense of human skin. Moreover the designed CatD 
substrate was modified by making it cell permeable and by the introduction of two 
fluorophores so that it can be used as an activity-based probe for the intracellular 
localisation and quantification of CatD activity within living cells. In general, the 
cellular uptake of fluorescein-labelled cell-penetrating peptides by human EBV-
transformed B cells was quantified by a new RP-HPLC based method. 
 
7.2 Zusammenfassung 
Der spezifische und empfindliche Nachweis von Proteaseaktivitäten in wässrigen 
biologischen Proben wie Blut, Urin, Schweiß oder Zelllysaten ist wichtig, da 
Proteasen häufig als Biomarker verwendet werden um zwischen Proben von 
Kranken und Gesunden zu unterscheiden. In den letzten Jahren wurden neue 
Proteomics-Anwendungen entwickelt um in einem Ansatz parallel mehrere 
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Parameter zu detektieren. Aufgrund dieser Tatsache werden spezifische Methoden, 
die sich zur Automatisierung eignen benötigt. In der vorliegenden Arbeit wird eine 
neue Methode zum Nachweis der CatD Aktivität vorgestellt, die sich prinzipiell auch 
auf beliebige andere Peptidsubstrate übertragen lässt und deshalb eine sinnvolle 
Ergänzung zu den bisher bekannten Enzymaktivitätstests darstellt. Der entwickelte 
Digest & Pull Down Assay wurde zur Bestimmung der CatD-Aktivität in biologischen 
Proben wie Zelllysaten und Schweiß verwendet. CatD konnte so in menschlichem 
Schweiß nachgewiesen werden. Des weiteren konnte gezeigt werden, dass CatD in 
Verbindung mit noch mindestens zwei weiteren Proteasen für die postsekretorische 
Prozessierung des antimikrobiellen Peptids DCD-1L in 12 DCD-1L abgeleitete 
Peptide verantwortlich ist, von denen mindestens ein Peptid (SSL-25) eine höhere 
antimikrobielle Aktivität besitzt als DCD-1L. Die angeborene Immunabwehr der Haut 
wird durch postsekretorische Prozessierung mittels CatD moduliert, indem 12 DCD-
1L abgeleitete Peptide generiert werden, die unterschiedliche antimikrobielle 
Aktivitäten besitzen. 
Die fluoreszenzbasierenden Visualisierungstechniken konfokale Laser-Raster-
Mikroskopie (CLSM) und Durchflusszytometrie (FACS) entwickelten sich in den 
letzten Jahren immer mehr zur bevorzugten Methode für zelluläre Untersuchungen. 
Die Entwicklung innovativer fluoreszierender Substanzen für diese Anwendungen ist 
deshalb von größter Bedeutung. Da Proteaseaktivitäten üblicherweise nur in 
Zelllysaten detektierbar sind, wurde ein neues zellgängiges Peptidsubstrat 
konstruiert, um Proteaseaktivitäten auch in lebende Zellen nachweisbar und sichtbar 
zu machen. Das R9-Substrat setzt sich aus dem zellgängigen Peptid R9 und dem 
spezifischen CatD-Substrat zusammen. An die zu spaltende Bindung grenzen die 
Fluorophore TAMRA und Carboxyfluorescein. Nach der Spaltung durch CatD ist der 
Quenching-Effekt der beiden Fluorophore aufgehoben und sowohl die TAMRA- als 
auch die Fluorescein-Fluoreszenz kann detektiert werden. In endolysosomalen 
Kompartimenten wird das R9-Substrat unter Zunahme des Fluoreszenzsignales 
gespalten und kann durch konfokale Laser-Raster-Mikroskopie oder 
durchflußzytometrisch nachgewiesen werden. Das vorgestellte Prinzip der 
zellpermeablen, doppelt markierten Peptidsubstrate und ihre Anwendung für 
zelluläre Untersuchungen ist ein innovativer und viel versprechender Ansatz, der 
eine sinnvolle Ergänzung zu herkömmlichen Techniken wie in vitro 
Verdauexperimente oder Western Blot Analysen bietet. 
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Wie bereits oben erwähnt, basieren viele bioanalytische Anwendungen auf 
Fluoreszenz-markierten Substanzen. Besonders die hydrolytisch stabilen, mit 
Fluorescein gekoppelten Peptide und Proteine finden eine breite Anwendung. 
Jedoch verringert die starke pH-Abhängigkeit von Fluorescein dessen Anwendung 
vor allem in sauren Puffersystemen, wie sie zum Beispiel bei gängigen RP-HPLC-
Systemen verwendet werden. Dieses Problem wurde durch die Entwicklung einer 
neuen RP-HPLC-Methode gelöst, die um den Faktor 40 sensitiver ist als 
herkömmliche Systeme und mit der gleichen Reproduzierbarkeit und Peak-
Auflösung arbeitet. Mit dieser Methode wurde die Aufnahme des zellgängigen 
Peptids Penetratin von humanen EBV-transformierten B-Zellen quantifiziert. 
Eine neue Methode zum Nachweis von CatD Aktivität basierend auf biotinylierten 
und fluoreszierenden Peptidsubstraten wurde entwickelt und auf verschiedene 
biologische Proben angewendet, insbesondere auf Schweiß, wo CatD zum ersten 
Mal nachgewiesen wurde. In diesem Zusammenhang wurde die physiologische 
Funktion von CatD im Schweiß gezeigt. CatD ist an der postsekretorischen 
Prozessierung des antimikrobiellen Peptids DCD-1L beteiligt und dadurch an der 
Modulation der Immunabwehr der Haut. Des weiteren wurde das konstruierte CatD-
Substrat zellgängig und durch die Kopplung mit zwei Fluorophoren nachweisbar 
gemacht und kann so zur intrazellulären Lokalisation von CatD-Aktivität verwendet 
werden. Die Internalisierung von fluoreszenzmarkierten, zellgängigen Peptiden von 
humanen EBV-transformierten B-Zellen im allgemeinen wurde durch eine neu 
entwickelte RP-HPLC-Methode quantifiziert. 
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9 Abbreviations 
For amino acids the suggestions of the IUPAC-IUB-commission for biological 
nomenclature [Eur. J. Biochem. 138, 9-37 (1984)] were applied. 
 
#    fraction 
ACN   acetonitrile 
Amca   7-Amino-4-methylcoumarin-3-acetic acid 
Cat    cathepsin 
CatD   cathepsin D 
CCE   crude cell extract 
CLSM   confocal laser scanning microscopy 
CPP   cell-penetrating peptide 
DABCYL   4’-dimethylaminoazobenzene-4-carboxylic acid 
DC    dendritic cell 
DG    digestion product 
E    endosomal fraction 
EC number  enzyme commission number 
EDANS   5-(2-aminoethyl) aminonaphthalene-1-sulfonic acid 
EDTA   ethylenediaminetetraacetic acid 
ESI    electrospray ionisation 
eq    equivalent 
FACS   fluorescence activated cell sorting 
Fluo   5-carboxyfluorescein 
IFN-γ   interferon γ 
L    lysosomal fraction 
LPS   lipopolysacharid 
MALDI matrix-assisted laser desorption/ionization 
MS  mass spectrometry 
MW   molecular weight 
m/z    mass/charge ratio 
Pbf    2, 2, 5, 7, 8-pentamethyl-dihydrobenzofuran-5-sulfonyl 
RP-HPLC   reversed-phase high-performance liquid chromatography 
RT    room temperature 
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SPPS   solid-phase peptide synthesis 
t    time 
TAMRA   5(6)-carboxytetramethylrhodamine 
TBST   Tris-buffered saline with Tween 
TBTU   2-(1H-benzotriazol-1-yl)-1, 1, 3, 3-tetramethyluronium 
tBu    tert.-butyl 
TCA   trichloroacetic acid 
TFA   trifluoroacetic acid 
TNF-α   tumor necrosis factor α 
Tris    tris(hydroxymethyl)aminomethane 
UV    ultraviolet 
V    volume 
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